RayKnowChina Research Map
Shortlist

ChangshaCentral South University (Xiangya)

Second Xiangya Hospital

中南大学湘雅二医院

Listed for 42 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Xiangya Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌25 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌6 papers led
  3. Hepatocellular carcinoma肝细胞癌55 papers led
  4. Stomach cancer胃癌32 papers led
  5. Lung cancer肺癌140 papers led11 open trials led
  6. Pancreatic cancer胰腺癌19 papers led
  7. Breast cancer乳腺癌72 papers led
  8. Glioma胶质瘤20 papers led
  9. Retinoblastoma视网膜母细胞瘤1 paper led
  10. Chordoma脊索瘤2 papers led
  11. Osteosarcoma骨肉瘤43 papers led
  12. Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
  13. Neuroblastoma神经母细胞瘤5 papers led
  14. Ewing sarcoma尤文肉瘤1 paper led
  15. Multiple myeloma多发性骨髓瘤14 papers led
  16. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病3 papers led
  17. Aplastic anaemia再生障碍性贫血6 papers led
  18. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  19. Lymphoma淋巴瘤13 papers led
  20. Beta thalassaemiaβ 地中海贫血2 papers led
  21. Haemophilia A血友病 A1 paper led
  22. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  23. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  24. Fanconi anaemia范可尼贫血5 papers led
  25. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病7 papers led
  26. IgG4-related diseaseIgG4相关性疾病1 paper led
  27. Myasthenia gravis重症肌无力6 papers led
  28. Wilson disease肝豆状核变性(Wilson 病)7 papers led
  29. Coronary heart disease冠心病36 papers led
  30. Congenital heart disease先天性心脏病40 papers led
  31. Scoliosis脊柱侧弯5 papers led
  32. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎3 papers led
  33. Takayasu arteritis大动脉炎5 papers led
  34. Idiopathic pulmonary fibrosis特发性肺纤维化18 papers led
  35. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病3 papers led
  36. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  37. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  38. Behçet disease白塞病1 paper led
  39. IgA nephropathyIgA 肾病14 papers led
  40. Osteogenesis imperfecta成骨不全症0 papers led
  41. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  42. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Hepatoblastoma, Moyamoya disease, Biliary atresia, Hepatic echinococcosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 25 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 4420222023: 3320232024: 8820242025: 992025

6 hospitals in Changsha for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIImmunotherapy
Departments in papersPathology / laboratory medicineMedical oncologyENT / head & neck surgeryNephrology

Over half of these papers are lab or animal studies.

Papers it led25
  1. A11 Peptide Enhances Radiosensitivity by Degrading EphA2 in Nasopharyngeal Carcinoma.2026Cancer scienceFree full text
  2. Programmed cell death in nasopharyngeal carcinoma: Mechanisms and therapeutic targets.2025Biochimica et biophysica acta. Reviews on cancer
  3. Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma.2025Cell death & diseaseFree full text
  4. The Combined Treatment of 4EGl-1 and MK-2206 Inhibits Nasopharyngeal Carcinoma Progress by Inducing Autophagy.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  5. SSTR2 exhibits a positive correlation with PD-L1 and predicts poor prognosis in nasopharyngeal carcinoma.2025International immunopharmacology
  6. Ferroptosis inhibition via the ROS-GPX4 axis drives microplastic-induced malignant progression of nasopharyngeal carcinoma.2025Journal of translational medicineFree full text
  7. Unveiling immune resistance mechanisms in nasopharyngeal carcinoma and emerging targets for antitumor immune response: tertiary lymphoid structures.2025Journal of translational medicineFree full text
  8. Nomograms Based on Blood-Based Biomarkers for Predicting Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients.2025Mediators of inflammationFree full text
  9. Deep learning based analysis of G3BP1 protein expression to predict the prognosis of nasopharyngeal carcinoma.2025PloS oneFree full text
  10. Nasogastric tube nutrition support enhances chemoradiotherapy compliance and alleviates mucosal reactions in nasopharyngeal carcinoma: a 856-case retrospective cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  11. Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2.2024Cell communication and signaling : CCSFree full text
  12. Predicting the overall survival and progression-free survival of nasopharyngeal carcinoma patients based on hemoglobin, albumin, and globulin ratio and classical clinicopathological parameters.2024Head & neck
  13. Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma.2024International journal of biological macromolecules
  14. G3BP1 Interact with JAK2 mRNA to Promote the Malignant Progression of Nasopharyngeal Carcinoma via Activating JAK2/STAT3 Signaling Pathway.2024International journal of biological sciencesFree full text
  15. SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma.2024Journal of clinical pathologyFree full text
  16. Comparative Proteomics Identified EXOSC1 as a Target Protein of Anticancer Peptide LVTX-8 in Nasopharyngeal Carcinoma Cells.2024Journal of proteome research
  17. LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/STIM1 axis.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  18. Nomograms based on the lymphocyte-albumin-neutrophil ratio (LANR) for predicting the prognosis of nasopharyngeal carcinoma patients after definitive radiotherapy.2024Scientific reportsFree full text
  19. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.2023BMJ openFree full text
  20. CircLASP1 silence strengthens the therapeutic effects of MK-2206 on nasopharyngeal cancer through upregulating miR-625.2023Cancer scienceFree full text
  21. Prognostic value of the fibrinogen albumin ratio index (FARI) in nasopharyngeal carcinoma patients undergoing radiotherapy.2023Scientific reportsFree full text
  22. Circ_0000523 regulates miR-1184/COL1A1/PI3K/Akt pathway to promote nasopharyngeal carcinoma progression.2022Apoptosis : an international journal on programmed cell death
  23. Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.2022International journal of biological sciencesFree full text
  24. Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients.2022Scientific reportsFree full text
  25. YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma.2022Scientific reportsFree full text
Chinese-language papers (not in the count)1
  1. Prognostic value of pretreatment peripheral blood hemoglobin×lymphocyte/monocyte ratio in patients with nasopharyngeal carcinoma.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  2. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Study sitePhase 1Start 2020-01
  3. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  4. A Trial of Endostar in Patients With Carcinoma of the Head and NeckStatus unknownNCT02902432Study sitePhase 2Start 2016-06
More papers found outside PubMed (not counted)30
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  3. CircARHGAP12 suppresses cisplatin-induced alkaliptosis in nasopharyngeal carcinoma through G3BP1-mediated upregulation of CA9 in an RNA G-quadruplex-dependent manner2025Research Squarepreprint
  4. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  5. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncologyconference-abstract
  6. Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study.2024Journal of Clinical Oncologyconference-abstract
  7. RETRACTED: METTL14 Promotes Lipid Metabolism Reprogramming and Sustains Nasopharyngeal Carcinoma Progression via Enhancing m6A Modification of ANKRD22 mRNA2024Research Squarepreprint
  8. Antitumor regimens with gemcitabine are safe for tumor patients with COVID-19.2023Journal of Clinical Oncologyconference-abstract
  9. Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L12023Venue not listedother
  10. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  11. Impact of radiotherapy for nasopharyngeal carcinoma on carotid stenosis risk: a meta-analysis2023Figsharedataset
  12. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Researchconference-abstract
  13. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  14. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  15. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  16. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  17. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  18. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  19. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  20. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  21. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  22. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  23. Fabrication of metformin and survivin siRNA encapsulated into polyethyleneimine-altered silk fibroin nanoparticles for the treatment of nasopharyngeal carcinoma2022Process Biochemistryarticle
  24. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancerconference-abstract
  25. Additional file 1 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figsharedataset
  26. Additional file 2 of Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO22021Figsharedataset
  27. Combination of CD47 Expression and SIRI as a Prognostic Factor in Nasopharyngeal Carcinoma Patients2021Research Squarepreprint
  28. Elevated transcriptional pausing of RNA polymerase II underlies acquired resistance to radiotherapy2021bioRxiv (Cold Spring Harbor Laboratory)preprint
  29. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncologyconference-abstract
  30. [Retracted] MicroRNA‑19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 22021Experimental and Therapeutic Medicinearticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 6 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 0020242025: 002025

3 hospitals in Changsha for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyMolecular markers & genomics
Departments in papersGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led6
  1. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles carrying miR-655-3p inhibit the development of esophageal cancer by regulating the expression of HIF-1α via a LMO4/HDAC2-dependent mechanism.2023Cell biology and toxicology
  2. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.2022Biochemical and biophysical research communications
  3. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.2022Frontiers in public healthFree full text
  4. Network analysis of genes associated with esophageal squamous cell carcinoma progression.2022Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  5. FBX4 mediates rapid cyclin D1 proteolysis upon DNA damage in immortalized esophageal epithelial cells.2021Biochemical and biophysical research communications
  6. Reduced LINC00551 expression promotes proliferation and invasion of esophageal squamous cancer by increase in HSP27 phosphorylation.2021Journal of cellular physiology
All its trials on ClinicalTrials.gov, any status1
  1. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
More papers found outside PubMed (not counted)5
  1. 470eP Multimodal imaging–clinical modeling to predict pathologic response after neoadjuvant chemoimmunotherapy for resectable ESCC2025Annals of Oncologyarticle
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 55 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
55
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 8820212022: 9920222023: 151520232024: 111120242025: 11112025

6 hospitals in Changsha for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07209813

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineGastroenterology / hepatology
Papers it led55
  1. Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growth.2026Journal of advanced researchFree full text
  2. Comparison of Diagnostic Accuracies of Radiomics and Non-radiomics Model for Preoperative Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2025Academic radiology
  3. High Fibroblast Activation Protein Expression in Hepatocellular Carcinoma: CT Imaging Features and Histological Characteristics.2025Academic radiology
  4. The Role of ROS and Its Sources in Tumorigenesis: Friend or Foe?2025Advanced biology
  5. ZDHHC12 Palmitoylates HDAC8 to Promote the Progression of Hepatocellular Carcinoma Associated with a Diet High in Saturated Fatty Acids.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. SLC1A4 Promotes Malignant Transformation of Hepatocellular Carcinoma by Activating the AKT Signaling.2025Analytical cellular pathology (Amsterdam)Free full text
  7. Synthesis and biological evaluation of 4-((3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)quinoline derivatives as novel potential transforming growth factor-β type 1 receptor inhibitors for hepatocellular carcinoma.2025Bioorganic chemistry
  8. Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma.2025Cancer gene therapyFree full text
  9. RAB40C recruiting TRIM21 facilitates the progression of hepatocellular carcinoma by stabilizing EGFR.2025Cell communication and signaling : CCSFree full text
  10. The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  11. Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis.2025PloS oneFree full text
  12. Skeletal muscle index/systemic immune-inflammation index (SMI/SII) ratio predicts prognosis in patients with hepatocellular carcinoma.2025World journal of surgical oncologyFree full text
  13. CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation.2024Biochimica et biophysica acta. Molecular basis of disease
  14. TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway.2024Cancer scienceFree full text
  15. Genomic and immune landscape in hepatocellular carcinoma: Implications for personalized therapeutics.2024Environmental toxicology
  16. METTL5 enhances the mRNA stability of TPRKB through m6A modification to facilitate the aggressive phenotypes of hepatocellular carcinoma cell.2024Experimental cell research
  17. Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  18. Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?2024Hepatology (Baltimore, Md.)
  19. A multi-omic analysis reveals that Gamabufotalin exerts anti-hepatocellular carcinoma effects by regulating amino acid metabolism through targeting STAMBPL1.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  20. Identification of the Roles of Coagulation-related Signature and its Key Factor RABIF in Hepatoma Cell Malignancy.2024Recent patents on anti-cancer drug discovery
  21. Subcutaneous adipose tissue/neutrophil-to-lymphocyte ratio is a potential biomarker in patients with hepatocellular carcinoma undergoing liver resection.2024Science progressFree full text
  22. Circular RNA DNAH14 molecular mechanism in an experimental model of hepatocellular carcinoma treated with Cobalt chloride to mimic the hypoxia-like response of transcatheter arterial chemoembolization.2024Scientific reportsFree full text
  23. Robotic anatomical resection for hepatocellular carcinoma located within segment 7 using the Glissonean approach.2024Updates in surgery
  24. Letter: repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma in ideal candidates - authors' reply.2023Alimentary pharmacology & therapeutics
  25. Editorial: is microwave ablation an alternative to liver resection for hepatocellular carcinoma? Authors' reply.2023Alimentary pharmacology & therapeutics
  26. An Integrated Liver Function, Systemic Inflammation, and Tumor Characteristic Score Predicts Prognosis in Hepatocellular Carcinoma After Curative Resection.2023Annals of surgical oncology
  27. ASO Author Reflections: The FIBA Score-A Novel Scoring System to Predict Outcomes in Hepatocellular Carcinoma After Surgical Resection or Transarterial Chemoembolization.2023Annals of surgical oncologyFree full text
  28. Mechanism underlying the effect of Pulsatilla decoction in hepatocellular carcinoma treatment: a network pharmacology and in vitro analysis.2023BMC complementary medicine and therapiesFree full text
  29. Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study.2023BMC medicineFree full text
  30. TRPM8 promotes hepatocellular carcinoma progression by inducing SNORA55 mediated nuclear-mitochondrial communication.2023Cancer gene therapy
  31. SLC12A5 promotes hepatocellular carcinoma growth and ferroptosis resistance by inducing ER stress and cystine transport changes.2023Cancer medicineFree full text
  32. Development and investigation of metabolism-associated risk assessment models for patients with viral hepatitis.2023Frontiers in cellular and infection microbiologyFree full text
  33. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.2023Frontiers in immunologyFree full text
  34. Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway.2023Functional & integrative genomics
  35. Association between antihypertensive drugs and hepatocellular carcinoma: A trans-ancestry and drug-target Mendelian randomization study.2023Liver international : official journal of the International Association for the Study of the Liver
  36. Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.2023Pharmacological research
  37. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.2023PloS oneFree full text
  38. Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization.2023Radiology
  39. Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern.2022Abdominal radiology (New York)Free full text
  40. Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability of treatment weighting analysis.2022Alimentary pharmacology & therapeutics
  41. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma.2022BMC medicineFree full text
  42. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.2022Cancer lettersFree full text
  43. A novel DNA methylation-driver gene signature for long-term survival prediction of hepatitis-positive hepatocellular carcinoma patients.2022Cancer medicineFree full text
  44. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.2022Cell reports
  45. Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data.2022Frontiers in immunologyFree full text
  46. A Risk Model Developed Based on Necroptosis Predicts Overall Survival for Hepatocellular Carcinoma and Identification of Possible Therapeutic Drugs.2022Frontiers in immunologyFree full text
  47. Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma.2022Gene
  48. A predictive model of incomplete response after transarterial chemoembolization for early or intermediate stage of hepatocellular carcinoma: consideration of hepatic angiographic and cross-sectional imaging.2021Abdominal radiology (New York)
  49. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.2021Drug deliveryFree full text
  50. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.2021Immunotherapy
  51. The roles and mechanisms of hypoxia in liver fibrosis.2021Journal of translational medicineFree full text
  52. Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.2021Journal of vascular and interventional radiology : JVIR
  53. Intra-platelet serotonin and YAP contributed to poor prognosis of hepatocellular carcinoma.2021Life sciences
  54. Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion.2021MedicineFree full text
  55. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.2021TheranosticsFree full text
Chinese-language papers (not in the count)4
  1. Research progress in cuproptosis in liver cancer.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Role of miR-5010-3p in predicting the prognosis of hepatocellular carcinoma.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Regulatory effect of PINK1/Parkin axis on mitophagy in isoniazide-induced hepatocellular injury.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  4. Mn-SOD alleviates methotrexate-related hepatocellular injury via GSK-3β affecting anti-oxidative stress of HO-1 and Drp1.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status1
  1. GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07209813Study sitePhase 2Start 2025-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 32 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
32
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 9920212022: 7720222023: 6620232024: 6620242025: 332025

4 hospitals in Changsha for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIPeritoneal spread & advanced disease
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncology
Papers it led32
  1. FTO Upregulates GLG1 Expression via m6A Methylation Modification to Facilitate Gastric Cancer Cell Migration and Invasion.2026Journal of gastroenterology and hepatology
  2. Association between metabolic syndrome and prognosis in elderly gastric cancer patients.2025Geriatric nursing (New York, N.Y.)
  3. Brucine Inhibits Gastric Cancer via Activation of Ferroptosis Through Regulating the NF-κB Signaling Pathway.2025Journal of biochemical and molecular toxicology
  4. Endoscopic ultrasound-guided bite-on-bite biopsy and endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of gastric tumors with negative malignant endoscopy biopsies: a retrospective cohort study.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  5. Silencing immune-infiltrating biomarker CCDC80 inhibits malignant characterization and tumor formation in gastric cancer.2024BMC cancerFree full text
  6. Circ_PABPC1 promotes the malignancy of gastric cancer through interacting with ILK to activate NF-κB pathway.2024Experimental cell research
  7. Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction.2024Frontiers in immunologyFree full text
  8. Exosomal miR-502-5p suppresses the progression of gastric cancer by repressing angiogenesis through the Wnt/β-catenin pathway.2024Irish journal of medical science
  9. Personalizing age of gastric cancer screening based on comorbidity in China: Model estimates of benefits, affordability and cost-effectiveness optimization.2024Preventive medicine
  10. Lesion size affects the risk of technical difficulty in gastric endoscopic submucosal dissection.2024Scientific reportsFree full text
  11. Explore the active ingredients and potential mechanisms of JianPi QingRe HuaYu Methods in the treatment of gastric inflammation-cancer transformation by network pharmacology and experimental validation.2023BMC complementary medicine and therapiesFree full text
  12. SMC1A facilitates gastric cancer cell proliferation, migration, and invasion via promoting SNAIL activated EMT.2023BMC gastroenterologyFree full text
  13. The characteristics and clinical relevance of tumor fusion burden in non-EBV (+) gastric cancer with MSS.2023BMC gastroenterologyFree full text
  14. Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis.2023Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  15. Circular RNA circPOFUT1 enhances malignant phenotypes and autophagy-associated chemoresistance via sequestrating miR-488-3p to activate the PLAG1-ATG12 axis in gastric cancer.2023Cell death & diseaseFree full text
  16. AGAP2-AS1 promotes the assembly of m6A methyltransferases and activation of the IL6/STAT3 pathway by binding with WTAP in the carcinogenesis of gastric cancer.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  17. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.2022BMJ openFree full text
  18. Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.2022Frontiers in public healthFree full text
  19. Long non-coding RNA SNHG1/microRNA-195-5p/Yes-associated protein axis affects the proliferation and metastasis of gastric cancer via the Hippo signaling pathway.2022Functional & integrative genomics
  20. Upregulated Solute Carrier SLC39A1 Promotes Gastric Cancer Proliferation and Indicates Unfavorable Prognosis.2022Genetics researchFree full text
  21. LncRNA NR2F2-AS1 functions as a tumor suppressor in gastric cancer through targeting miR-320b/PDCD4 pathway.2022Histology and histopathology
  22. Kinesin family member 2A links with advanced tumor stage, reduced chemosensitivity and worse prognosis in gastric cancer.2022Journal of clinical laboratory analysisFree full text
  23. Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.2022PharmacoEconomics
  24. STAM2 knockdown inhibits proliferation, migration, and invasion by affecting the JAK2/STAT3 signaling pathway in gastric cancer.2021Acta biochimica et biophysica Sinica
  25. Expression and prognosis analyses of BUB1, BUB1B and BUB3 in human sarcoma.2021AgingFree full text
  26. The prognostic value of circular RNA regulatory genes in competitive endogenous RNA network in gastric cancer.2021Cancer gene therapy
  27. LINC01133 hampers the development of gastric cancer through increasing somatostatin via binding to microRNA-576-5p.2021Epigenomics
  28. Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.2021Journal of immunology researchFree full text
  29. Efficacy and safety of submucosal tunneling endoscopic resection for gastric submucosal tumors: a systematic review and meta-analysis.2021Revista espanola de enfermedades digestivas
  30. Factors that predict the technical difficulty during endoscopic full-thickness resection of a gastric submucosal tumor.2021Revista espanola de enfermedades digestivas
  31. Factors predicting technical difficulties during endoscopic submucosal excavation for gastric submucosal tumor.2021The Journal of international medical researchFree full text
  32. Value of HMGB1 expression for assessing gastric cancer severity: a systematic meta-analysis.2021The Journal of international medical researchFree full text
All its trials on ClinicalTrials.gov, any status6
  1. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  2. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  3. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  4. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  5. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  6. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 140 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.6%.

Papers led
140
2021–2025
Trials led
15
any status, ClinicalTrials.gov
Open trials led
11
recruiting or about to
Open trials as a site
12
led by another institution
Papers led per year
2021: 262620212022: 222220222023: 303020232024: 282820242025: 32322025

6 hospitals in Changsha for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 23

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT06951646

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 12 listed hospitals as study sitesChangsha, Chongqing, Nanchang, Nanning, Shenyang, Taiyuan, Wuhan, Xinxiang

  2. Recruiting
    Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07886047

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha

  3. Recruiting
    Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07886229

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha

  4. Recruiting
    Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07066813

    Age not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  5. Recruiting
    Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07820423

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  6. Recruiting
    Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT05979818

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya HospitalChangsha

  7. Recruiting
    Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06699979

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  8. Recruiting
    The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06975384

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  9. Recruiting
    Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
    Phase
    Not given
    Started
    2021-09
    Posted
    Registry
    NCT05598528

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  10. Recruiting
    The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
    Phase
    Not given
    Started
    2020-06
    Posted
    Registry
    NCT05477979

    Age 18 years to Not stated (registered criteria)

    Led by Second Xiangya HospitalChangsha

  11. Not yet recruiting
    ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
    Phase
    Not given
    Started
    2023-04
    Posted
    Registry
    NCT05822284

    Age 18 years to 75 years (registered criteria)

    Led by Second Xiangya HospitalChangsha

  12. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  13. Recruiting
    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07554339

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen

  14. Recruiting
    A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06793215

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan

  15. Recruiting
    Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06864624

    Age 18 years to Not stated (registered criteria)

    Led by Tangdu Hospital; 2 listed hospitals as study sitesChangsha, Xi'an, Yinchuan

  16. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  17. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  18. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  19. Recruiting
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06422143

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou

  20. Recruiting
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05920356

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou

  21. Recruiting
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170788

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou

  22. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  23. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineRadiology / nuclear medicineGastroenterology / hepatology
Papers it led140
  1. circ_PPAPDC1A is Associated with Brain Metastasis of Non-Small-Cell Lung Cancer via the miR-30a-3p/SPOCK1 Pathway.2026Annals of surgical oncology
  2. Psychological Distress in Surgical Lung Cancer Patients: Trajectories, Influencing Factors and Impacts on Quality of Life.2026Journal of clinical nursing
  3. Cx58 is associated with the metastasis of non-small cell lung cancer via MEF2B/Cx58 axis.2025Acta biochimica et biophysica SinicaFree full text
  4. Assembly of a biomimetic copper-based nanocomplex for alleviating hypoxia to enhance cuproptosis against osteosarcoma and lung metastasis.2025Acta biomaterialia
  5. Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p-STAT3 Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases.2025BMC health services researchFree full text
  7. Experiences of health information-seeking behaviour in preoperative patients with lung cancer: a qualitative study in China.2025BMJ openFree full text
  8. GIMAP1 interacts with TMX1 to improve lung adenocarcinoma prognosis by influencing tumor immune microenvironment.2025Biochimica et biophysica acta. Molecular basis of disease
  9. A pan-cancer analysis of MARCH8: molecular characteristics, clinical relevance, and immuno-oncology features.2025Cancer biology & therapyFree full text
  10. The YTHDF3-DT/miR-301a-3p /INHBA axis attenuates autophagy-dependent ferroptosis in lung adenocarcinoma.2025Cancer letters
  11. HROB Induces Lung Adenocarcinoma Progression via ZC3HC1-CCNB1 Axis Regulation and Cell Cycle Dysregulation.2025Cancer scienceFree full text
  12. Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma.2025Clinical and experimental medicineFree full text
  13. Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutations.2025Clinical epigeneticsFree full text
  14. lncRNA NR_146969 promotes the progression of lung adenocarcinoma.2025Experimental cell research
  15. EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation.2025Expert review of anticancer therapy
  16. Lactylation increases the stability of RBM15 to drives m6A modification in non-small-cell lung cancer cells.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  17. Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in China.2025Frontiers in immunologyFree full text
  18. USP10-stabilized IGF2BP3 promotes tumor growth via m6A-modified SKP2 mRNA in non-small-cell lung cancer.2025International journal of biological macromolecules
  19. Prevalence and Risk Factors of Psychological Distress in Patients With Early-Stage Lung Cancer During Preoperative Period: A Cross-Sectional Study.2025Journal of clinical nursing
  20. Dose-dependent M2 macrophage polarization induced by Talaromyces marneffei promotes lung cancer cell growth via arginine-ornithine-cycle activation.2025Medical microbiology and immunology
  21. ALKBH5-Mediated m6A Modification of XBP1 Facilitates NSCLC Progression Through the IL-6-JAK-STAT3 Pathway.2025Molecular carcinogenesis
  22. T cell exhaustion‑related gene CD79B predicts prognosis, inhibits malignant progression and promotes tumor‑associated macrophage M1‑like polarization in lung adenocarcinoma.2025Oncology reportsFree full text
  23. A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma.2025PeerJFree full text
  24. SRSF3 undergoes phase separation in lung cancer and is associated with immunity and ferroptosis.2025Scientific reportsFree full text
  25. Deep-learning based electromagnetic navigation system for transthoracic percutaneous puncture of small pulmonary nodules.2025Scientific reportsFree full text
  26. MicroRNA-150-3p enhances the antitumour effects of CGP57380 and is associated with a favourable prognosis in non-small cell lung cancer.2025Scientific reportsFree full text
  27. Tumor detection on bronchoscopic images by unsupervised learning.2025Scientific reportsFree full text
  28. Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions.2025Seminars in cancer biology
  29. Psychological resilience in newly diagnosed lung cancer patients: Trajectories and influencing factors.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  30. Anxiety and self-efficacy in Chinese lung cancer patients: cross-lagged effects and the mediation of resilience.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  31. Early Palliative Care in Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.2025The American journal of hospice & palliative care
  32. Clinical and Genetic Characteristics of Early-Onset Lung Adenocarcinoma in a Large Chinese Cohort.2025The Annals of thoracic surgery
  33. Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.2025World journal of surgical oncologyFree full text
  34. Peripheral blood inflammatory markers as predictive and prognostic indicators in neoadjuvant immunotherapy for non-small cell lung cancer.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  35. Habitat Imaging With Tumoral and Peritumoral Radiomics for Prediction of Lung Adenocarcinoma Invasiveness on Preoperative Chest CT: A Multicenter Study.2024AJR. American journal of roentgenology
  36. A Hybrid Nanoadjuvant Simultaneously Depresses PD-L1/TGF-β1 and Activates cGAS-STING Pathway to Overcome Radio-Immunotherapy Resistance.2024Advanced materials (Deerfield Beach, Fla.)
  37. Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing.2024Advances in therapy
  38. Anxiety and depression in lung cancer: effect of psychological interventions - network meta-analysis.2024BMJ supportive & palliative care
  39. Comprehensive Analysis for Predicting Prognoses and Immune Responses of m6A-Related lncRNAs in Women with Lung Adenocarcinoma.2024Biochemical genetics
  40. EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.2024Cancer letters
  41. Sevoflurane inhibits lung cancer development by promoting FUS1 transcription via downregulating IRF6.2024Carcinogenesis
  42. Efficacy and safety of microwave ablation and its synergistic potential in the treatment of early-stage non-small cell lung cancer.2024Clinical imaging
  43. Blood Group Antigen A Carriers Exhibit an Extended Progression-Free Survival with no more Immune-Related Adverse Events.2024Clinical pharmacology and therapeutics
  44. First report of a successful surgical management of left atrial myxoma coexisting with pulmonary squamous cell carcinoma and thymic cyst.2024European journal of medical researchFree full text
  45. Effect of an integrated narrative program (INP) on quality of life among patients with non-small cell lung cancer (NSCLC): An experimental trial.2024European journal of oncology nursing : the official journal of European Oncology Nursing SocietyRCT
  46. Effect of digital storytelling intervention on resilience, self-efficacy and quality of life among patients with non-small cell lung cancer (NSCLC): A randomized controlled trial.2024European journal of oncology nursing : the official journal of European Oncology Nursing SocietyRCT
  47. Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial.2024Expert review of pharmacoeconomics & outcomes research
  48. Efficacy of combined surgery and pembrolizumab for the treatment of pulmonary large cell carcinoma: a case report.2024Frontiers in immunologyFree full text
  49. Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction.2024Frontiers in immunologyFree full text
  50. Integrated bioinformatics analysis of nucleotide metabolism based molecular subtyping and biomarkers in lung adenocarcinoma.2024Frontiers in immunologyFree full text
  51. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis.2024Frontiers in immunologyFree full text
  52. Case report: Pathological complete response induced by immunochemotherapy in a case of Pulmonary Sarcomatoid Carcinoma staged IIIA-N2.2024Frontiers in immunologyFree full text
  53. Unraveling the Connection: Extracellular Vesicles and Non-Small Cell Lung Cancer.2024International journal of nanomedicineFree full text
  54. Family resilience and vulnerability of patients at diagnosis of lung cancer: A qualitative study.2024Journal of clinical nursing
  55. RBM15 drives the progression of lung adenocarcinoma by regulating N6-methyladenosine-mediated LDHA mRNA stability.2024Life sciences
  56. Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities.2024Lung cancer (Amsterdam, Netherlands)
  57. circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC).2024Molecular cancerFree full text
  58. Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.2024Nature medicineFree full text
  59. Trans-3, 5, 4'-trimethoxystilbene restrains non-small-cell lung carcinoma progression via suppressing M2 polarization through inhibition of m6A modified circPACRGL-mediated Hippo signaling.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  60. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.2024PloS oneFree full text
  61. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.2024The journal of pathology. Clinical researchFree full text
  62. Pulmonary mucosa-associated lymphoid tissue lymphoma: insights from a 15-year study at a single institution involving 14 clinical cases.2024World journal of surgical oncologyFree full text
  63. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.2023Advances in therapy
  64. The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China.2023Advances in therapy
  65. Exploration of lung mycobiome in the patients with non-small-cell lung cancer.2023BMC microbiologyFree full text
  66. The effectiveness of postoperative rehabilitation interventions that include breathing exercises to prevent pulmonary atelectasis in lung cancer resection patients: a systematic review and meta-analysis.2023BMC pulmonary medicineFree full text
  67. A novel mutation (p.Y24N) in NHP2 leads to idiopathic pulmonary fibrosis and lung carcinoma chronic obstructive lung disease by disrupting the expression and nucleocytoplasmic localization of NHP2.2023Biochimica et biophysica acta. Molecular basis of disease
  68. Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer.2023Cancer medicineFree full text
  69. Increased expression of FAT4 suppress metastasis of lung adenocarcinoma through regulating MAPK pathway and associated with immune cells infiltration.2023Cancer medicineFree full text
  70. Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study.2023Cancer medicineFree full text
  71. Real-world comprehensive diagnosis and "Surgery + X" treatment strategy of early-stage synchronous multiple primary lung cancer.2023Cancer medicine
  72. Genetic, DNA methylation, and immune profile discrepancies between early-stage single primary lung cancer and synchronous multiple primary lung cancer.2023Clinical epigeneticsFree full text
  73. Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells.2023Communications biologyFree full text
  74. Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study.2023Frontiers in endocrinologyFree full text
  75. Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer.2023Frontiers in immunologyFree full text
  76. Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil.2023Frontiers in immunologyFree full text
  77. Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer.2023Frontiers in immunologyRCTFree full text
  78. YAP1 synergize with YY1 transcriptional co-repress DUSP1 to induce osimertinib resistant by activating the EGFR/MAPK pathway and abrogating autophagy in non-small cell lung cancer.2023International journal of biological sciencesFree full text
  79. Thermal ablation versus radiotherapy for inoperable stage III non-small cell lung cancer: a propensity score matching analysis.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  80. Temperature-Sensitive Nanocarbon Hydrogel for Photothermal Therapy of Tumors.2023International journal of nanomedicineFree full text
  81. Caregiver burden for informal caregivers of patients after surgical treatment of early-stage lung cancer.2023Journal of clinical nursing
  82. Computed Tomography-derived intratumoral and peritumoral radiomics in predicting EGFR mutation in lung adenocarcinoma.2023La Radiologia medicaFree full text
  83. circ_rac GTPase-Activating Protein 1 Facilitates Stemness and Metastasis of Non-Small Cell Lung Cancer via Polypyrimidine Tract-Binding Protein 1 Recruitment to Promote Sirtuin-3-Mediated Replication Timing Regulatory Factor 1 Deacetylation2023Laboratory investigation; a journal of technical methods and pathology
  84. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.2023Lung cancer (Amsterdam, Netherlands)
  85. Identification of common genetic features and pathways involved in pulmonary lymphangioleiomyomatosis and ER-positive breast cancer.2023MedicineFree full text
  86. Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues.2023OncoimmunologyFree full text
  87. Comprehensive analysis of cuproptosis and copper homeostasis genotyping and related immune land scape in lung adenocarcinoma.2023Scientific reportsFree full text
  88. Factors affecting lung cancer patients' intention to perform early postoperative exercise: a qualitative study based on theory of planned behavior.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  89. Mutation of TP53 Confers Ferroptosis Resistance in Lung Cancer Through the FOXM1/MEF2C Axis.2023The American journal of pathology
  90. Deregulation of HSF1-mediated endoplasmic reticulum unfolded protein response promotes cisplatin resistance in lung cancer cells.2023The FEBS journal
  91. RNA m6A methyltransferase METTL14 promotes the procession of non-small cell lung cancer by targeted CSF1R.2023Thoracic cancerFree full text
  92. Clinical features and risk factors of lung cancer in elderly patients with dermatomyositis.2023Thoracic cancerFree full text
  93. Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.2022BMC cancerFree full text
  94. Effectiveness of a perioperative support programme to reduce psychological distress for family caregivers of patients with early-stage lung cancer: study protocol for a randomised controlled trial.2022BMJ openFree full text
  95. Incidence and Prognosis Nomogram of Small Solitary Lung Cancer (≤2 cm) With Extra-Thoracic Metastasis at Initial Diagnosis:A Population-Based Study.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  96. Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer.2022Cell death & diseaseFree full text
  97. Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies.2022Chemotherapy
  98. Metagenomic analysis of the microbiome of lung adenocarcinoma with pure ground-glass opacity.2022Clinical and translational medicineFree full text
  99. Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.2022Current opinion in oncology
  100. Complete pathological remission after neoadjuvant ensartinib in patients with locally advanced lung adenocarcinoma and with CTLC-ALK and ALK-DHX8 rearrangements.2022European journal of cancer (Oxford, England : 1990)
  101. Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation.2022European journal of cancer (Oxford, England : 1990)
  102. DNA methylation in pulmonary fibrosis and lung cancer.2022Expert review of respiratory medicineFree full text
  103. Single-Cell RNA Sequencing Unravels Distinct Tumor Microenvironment of Different Components of Lung Adenocarcinoma Featured as Mixed Ground-Glass Opacity.2022Frontiers in immunologyFree full text
  104. A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.2022Frontiers in immunologyFree full text
  105. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.2022Frontiers in public healthFree full text
  106. Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.2022Frontiers in public healthFree full text
  107. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.2022Frontiers in public healthFree full text
  108. Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis.2022Future oncology (London, England)
  109. Epithelial-mesenchymal reprogramming by KLF4-regulated Rictor expression contributes to metastasis of non-small cell lung cancer cells.2022International journal of biological sciencesFree full text
  110. Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules.2022International journal of cancerFree full text
  111. Smoking-associated upregulation of CBX3 suppresses ARHGAP24 expression to activate Rac1 signaling and promote tumor progression in lung adenocarcinoma.2022OncogeneFree full text
  112. Overexpression of LINC00551 promotes autophagy-dependent ferroptosis of lung adenocarcinoma via upregulating DDIT4 by sponging miR-4328.2022PeerJFree full text
  113. Overexpression of p-4EBP1 associates with p-eIF4E and predicts poor prognosis for non-small cell lung cancer patients with resection.2022PloS oneFree full text
  114. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.2022Scientific reportsFree full text
  115. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.2021Advances in therapy
  116. Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer.2021Advances in therapy
  117. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.2021Advances in therapy
  118. TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.2021BMC cancerFree full text
  119. CircRNA_100565 contributes to cisplatin resistance of NSCLC cells by regulating proliferation, apoptosis and autophagy via miR-337-3p/ADAM28 axis.2021Cancer biomarkers : section A of Disease markersFree full text
  120. Overexpression of FADD and Bcl-XS proteins as novel prognostic biomarkers for surgically resected non-small cell lung cancer.2021Cancer biomarkers : section A of Disease markersFree full text
  121. circRACGAP1 promotes non-small cell lung cancer proliferation by regulating miR-144-5p/CDKL1 signaling pathway.2021Cancer gene therapy
  122. Impact of an Animation Education Program on Promoting Compliance With Active Respiratory Rehabilitation in Postsurgical Lung Cancer Patients: A Randomized Clinical Trial.2021Cancer nursingRCT
  123. MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer.2021Clinical lung cancer
  124. A Staging Auxiliary Diagnosis Model for Nonsmall Cell Lung Cancer Based on the Intelligent Medical System.2021Computational and mathematical methods in medicineFree full text
  125. Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome.2021Experimental and molecular pathology
  126. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.2021Frontiers in immunologyFree full text
  127. The complex role of AIM2 in autoimmune diseases and cancers.2021Immunity, inflammation and diseaseFree full text
  128. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.2021Immunotherapy
  129. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.2021International immunopharmacology
  130. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.2021Journal for immunotherapy of cancerFree full text
  131. Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma.2021Journal of translational medicineFree full text
  132. Aberrant Expression of β-Catenin Correlates with Infiltrating Immune Cells and Prognosis in NSCLC.2021Pathology oncology research : PORFree full text
  133. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.2021PloS oneRCTFree full text
  134. Construction of ceRNA network to identify the lncRNA and mRNA related to non-small cell lung cancer.2021PloS oneFree full text
  135. Bioinformatics prediction of differential miRNAs in non-small cell lung cancer.2021PloS oneFree full text
  136. Resilience process and its protective factors in long-term survivors after lung cancer surgery: a qualitative study.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  137. Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis.2021Technology in cancer research & treatmentFree full text
  138. The combination of fibrinogen concentrations and the platelet-to-lymphocyte ratio predicts survival in patients with advanced lung adenocarcinoma treated with EGFR-TKIs.2021The Journal of international medical researchFree full text
  139. Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics.2021Thoracic cancerFree full text
  140. A novel technique for preoperative localization of pulmonary nodules using a mixture of tissue adhesive and iohexol under computed tomography guidance: A 140 patient single-center study.2021Thoracic cancerFree full text
Chinese-language papers (not in the count)8
  1. Alectinib treatment for 2 non-small cell lung carcinoma patients carrying different novel ALK fusions.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Hyperprogression of buccal squamous cell carcinoma accompanied by carotid sinus syndrome: A case report.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. [Effect of glucocorticoids on the efficacy of non-small cell lung cancer patients treated with immune-checkpoint inhibitors].2024Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  4. Artificial intelligence in lung cancer: Application and future thinking.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  5. Primary pulmonary artery sarcoma complicated with pulmonary embolism and pulmonary tuberculosis: A case report and literature review.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  6. [Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  7. A modified approach of port-access lymphadectomy for locally advanced non-small cell lung cancer: A single center experience.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  8. Lung adenocarcinoma misdiagnosed as IgG4-related lung disease: A case report and literature review.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status60
  1. ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)RecruitingNCT06951646Lead sponsorPhase 2Start 2026-03
  2. Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung CancerRecruitingNCT07886047Lead sponsorPhase 1Start 2026-05
  3. Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung CancerRecruitingNCT07886229Lead sponsorPhase 1Start 2026-06
  4. The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung CancerRecruitingNCT06975384Lead sponsorStart 2024-11
  5. Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung CancerRecruitingNCT05979818Lead sponsorPhase 1Start 2024-11
  6. ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction ChemoimmunotherapyNot yet recruitingNCT05822284Lead sponsorStart 2023-04
  7. Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)RecruitingNCT05598528Lead sponsorStart 2021-09
  8. The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)RecruitingNCT05477979Lead sponsorStart 2020-06
  9. A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLCStatus unknownNCT05360979Lead sponsorPhase 2Start 2022-05
  10. A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)CompletedNCT04636762Lead sponsorPhase 2Start 2020-06
  11. Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic AirspacesRecruitingNCT07820423Lead (inferred)Start 2025-05
  12. Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic AirspacesRecruitingNCT07066813Lead (inferred)Start 2025-06
  13. Multi-omics Study of Early-stage Lung Cancer With Distinct PhenotypesRecruitingNCT06699979Lead (inferred)Start 2024-08
  14. ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLCActive, not recruitingNCT05198154Lead (inferred)Start 2022-01
  15. Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)Status unknownNCT03060343Lead (inferred)Early phase 1Start 2016-11
  16. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT07222566Study sitePhase 3Start 2026-01
  17. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)RecruitingNCT07554339Study sitePhase 3Start 2026-06
  18. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Study sitePhase 2Start 2025-06
  19. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingNCT06793215Study sitePhase 3Start 2025-10
  20. Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCRecruitingNCT06864624Study sitePhase 2Start 2025-02
  21. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Study sitePhase 3Start 2024-05
  22. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingNCT06422143Study sitePhase 3Start 2024-06
  23. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Study sitePhase 3Start 2024-03
  24. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Study sitePhase 3Start 2023-11
  25. A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNot yet recruitingNCT05990127Study sitePhase 3Start 2023-11
  26. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Study sitePhase 3Start 2023-12
  27. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Study sitePhase 1/Phase 2Start 2021-09
  28. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerTerminatedNCT06897579Study sitePhase 2Start 2025-04
  29. A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCActive, not recruitingNCT06745323Study sitePhase 2Start 2025-02
  30. A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Study sitePhase 3Start 2024-10
  31. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active, not recruitingNCT06305754Study sitePhase 3Start 2024-06
  32. A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Study sitePhase 3Start 2024-06
  33. A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Active, not recruitingNCT06593522Study sitePhase 2Start 2024-12
  34. Induction Lorlatinib in Stage III Non-small Cell Lung CancerActive, not recruitingNCT05740943Study sitePhase 2Start 2023-03
  35. A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung CancerCompletedNCT06029127Study sitePhase 2Start 2023-10
  36. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active, not recruitingNCT06074588Study sitePhase 3Start 2023-11
  37. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Study sitePhase 3Start 2023-02
  38. Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.Status unknownNCT05922345Study sitePhase 3Start 2023-06
  39. Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)TerminatedNCT05226598Study sitePhase 3Start 2022-03
  40. A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerActive, not recruitingNCT05353257Study sitePhase 3Start 2022-05
  41. AP-L1898 Capsule in Patients With Non-small Cell Lung CancerTerminatedNCT04993391Study sitePhase 1/Phase 2Start 2021-07
  42. Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung CancerCompletedNCT04952597Study sitePhase 2Start 2021-07
  43. A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingNCT04603807Study sitePhase 3Start 2021-09
  44. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT04921358Study sitePhase 3Start 2021-07
  45. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedNCT04746924Study sitePhase 3Start 2021-05
  46. Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Study sitePhase 3Start 2020-07
  47. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  48. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Study sitePhase 1Start 2020-01
  49. Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Study sitePhase 3Start 2020-12
  50. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Study sitePhase 3Start 2018-11
  51. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerCompletedNCT03594747Study sitePhase 3Start 2018-07
  52. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Study sitePhase 3Start 2018-08
  53. A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Study sitePhase 2/Phase 3Start 2017-09
  54. Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and LobectomyStatus unknownNCT02360761Study sitePhase 3Start 2016-01
  55. Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCCompletedNCT02273375Study sitePhase 3Start 2015-02
  56. Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLCCompletedNCT02504489Study sitePhase 3Start 2015-12
  57. A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous ChemotherapyCompletedNCT01364012Study sitePhase 3Start 2011-05
  58. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung CancerCompletedNCT03117335Study sitePhase 3Start 2011-11
  59. Modified Video-assisted Thoracoscopic Surgery (VATS) Lobectomy for Early-stage Non-small Cell Lung Cancer (NSCLC)Status unknownNCT01337037Study siteStart 2011-04
  60. Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01040780Study sitePhase 3Start 2009-02

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 19 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 5520212022: 5520222023: 4420232024: 3320242025: 222025

5 hospitals in Changsha for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06946901

    Age 18 years to 80 years (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteChangsha, Shanghai

  2. Recruiting
    Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06799637

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Kunming, Luoyang, Shanghai, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led19
  1. Investigation of potential toxicity associated with long-term amitriptyline exposure: Evidence from genomics.2025Ecotoxicology and environmental safety
  2. Optimizing pancreatic enucleation for benign tumors: the role of pre-placed pancreatic duct stents-a retrospective cohort study.2025Surgical endoscopy
  3. An immunogenic cell death-related gene expression signature in predicting prognosis of pancreatic ductal adenocarcinoma.2024BMC genomicsFree full text
  4. ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression.2024Nature communicationsFree full text
  5. Explainable cancer factors discovery: Shapley additive explanation for machine learning models demonstrates the best practices in the case of pancreatic cancer.2024Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  6. Distribution of autoantibodies to insulinoma-associated antigen-2 and zinc transporter 8 in type 1 diabetes and latent autoimmune diabetes: A nationwide, multicentre, cross-sectional study.2023Diabetes/metabolism research and reviewsFree full text
  7. Prognosis prediction and comparison between pancreatic signet ring cell carcinoma and pancreatic duct adenocarcinoma: a retrospective observational study.2023Frontiers in endocrinologyFree full text
  8. KMT2D links TGF-β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity.2023International journal of cancerFree full text
  9. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion.2023The Journal of clinical investigationFree full text
  10. Pancreatic duct dilatation and pancreatic head mass caused by the rare finding of a whole Ascaris within the pancreatic duct.2022EndoscopyFree full text
  11. A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma.2022Frontiers in immunologyFree full text
  12. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.2022Molecular oncologyFree full text
  13. USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression.2022Molecular oncologyFree full text
  14. FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression.2022Oncogene
  15. circSFMBT1 promotes pancreatic cancer growth and metastasis via targeting miR-330-5p/PAK1 axis.2021Cancer gene therapy
  16. HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3.2021Cancer medicineFree full text
  17. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer.2021Cell death & diseaseFree full text
  18. Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment.2021Drug design, development and therapyFree full text
  19. KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.2021Experimental biology and medicine (Maywood, N.J.)Free full text
All its trials on ClinicalTrials.gov, any status2
  1. The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical TrialRecruitingNCT06946901Study sitePhase 2Start 2025-04
  2. Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsRecruitingNCT06799637Study sitePhase 1/Phase 2Start 2023-12

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 72 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
72
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 6620212022: 131320222023: 191920232024: 191920242025: 15152025

4 hospitals in Changsha for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  2. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  3. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  4. Recruiting
    Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06551220

    Age 18 years to 80 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai

  5. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineGastroenterology / hepatology
Papers it led72
  1. Thermosensitive Hydrogel-Mediated Chemo-Photothermal Combined Immunotherapy for Triple-Negative Breast Cancer.2025ACS applied materials & interfaces
  2. Red Blood Cell Membrane-Camouflaged Nanoparticles for Synergistic Sonodynamic Therapy and TGF-β Inhibition to Reprogram Immunosuppressive Tumor Microenvironment.2025ACS applied materials & interfaces
  3. Serine/Threonine Kinase 33 as a Novel Target of Bufalin in Treatment of Triple-Negative Breast Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Identification of a Novel Substrate for eEF2K and the AURKA-SOX8 as the Related Pathway in TNBC.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials.2025Annals of surgical oncology
  6. Axillary lymph node metastasis in breast cancer: from historical axillary surgery to updated advances in the preoperative diagnosis and axillary management.2025BMC surgeryFree full text
  7. MnO2-based nanoparticles remodeling tumor micro-environment to augment sonodynamic immunotherapy against breast cancer.2025Biomaterials science
  8. Design and synthesis of tetrazole tethered quinazoline derivatives via azide-isocyanide cross-coupling reaction: Exploring the utility as anticancer agents via the SRC kinase inhibition in breast cancer.2025Bioorganic chemistry
  9. PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation.2025Cancer medicineFree full text
  10. GPX4-AUTAC induces ferroptosis in breast cancer by promoting the selective autophagic degradation of GPX4 mediated by TRAF6-p62.2025Cell death and differentiationFree full text
  11. Inhibition of UCH-L1 enhances immunotherapy efficacy in triple-negative breast cancer by stabilizing PD-L1.2025European journal of pharmacology
  12. Multi-omics analysis reveals ultraviolet response insights for immunotherapy and prognosis.2025Frontiers in immunologyFree full text
  13. Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection.2025Future oncology (London, England)Free full text
  14. Dual-Function RNA Biomarkers: Integrating Relapse Prediction and Immune Profiling in Triple-Negative Breast Cancer.2025International journal of medical sciencesFree full text
  15. A lipid metabolism-related gene signature for risk stratification and prognosis prediction in patients with breast cancer.2025Scientific reportsFree full text
  16. Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple-Negative Breast Cancer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  17. Comprehensive pancancer analysis reveals that LPCAT1 is a novel predictive biomarker for prognosis and immunotherapy response.2024Apoptosis : an international journal on programmed cell death
  18. Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.2024BMC cancerFree full text
  19. Comparing long-term prognosis following different surgical methods in patients with early stage breast cancer and obesity: a retrospective cohort study in China.2024BMJ openFree full text
  20. Impact of obesity on sentinel lymph node biopsy outcomes and survival in breast cancer patients: A single-center retrospective study.2024Cancer medicineFree full text
  21. MEIS2 suppresses breast cancer development by downregulating IL10.2024Cancer reports (Hoboken, N.J.)Free full text
  22. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.2024European journal of medical researchFree full text
  23. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study.2024Frontiers in endocrinologyFree full text
  24. Interleukin signaling in the regulation of natural killer cells biology in breast cancer.2024Frontiers in immunologyFree full text
  25. Circulating tumor DNA: from discovery to clinical application in breast cancer.2024Frontiers in immunologyFree full text
  26. Family hardiness among primary caregivers of breast cancer patients in Hunan Province: a cross-sectional study exploring the relationship with attachment and caregiver preparedness.2024Frontiers in public healthFree full text
  27. Spatiotemporal-controllable ROS-responsive camptothecin nano-bomb for chemo/photo/immunotherapy in triple-negative breast cancer.2024Journal of nanobiotechnologyFree full text
  28. Germacrone alleviates breast cancer-associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF-κB signaling pathways.2024Phytotherapy research : PTR
  29. Prognostic model based on tumor stemness genes for triple-negative breast cancer.2024Scientific reportsFree full text
  30. Prognostic and immune correlation of IDO1 promoter methylation in breast cancer.2024Scientific reportsFree full text
  31. Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy.2024Scientific reportsFree full text
  32. Value of contrast-enhanced ultrasound in differentiating granulomatous mastitis from invasive ductal carcinoma.2024The British journal of radiology
  33. Comment on: Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis.2024The British journal of surgery
  34. Associations between serum metabolites and female cancers: A bidirectional two-sample mendelian randomization study.2024The Journal of steroid biochemistry and molecular biology
  35. Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  36. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.2023BMC health services researchFree full text
  37. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.2023Breast cancer research : BCRFree full text
  38. ZNF451 favors triple-negative breast cancer progression by enhancing SLUG-mediated CCL5 transcriptional expression.2023Cell reports
  39. Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer.2023Chemico-biological interactions
  40. Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.2023Clinical therapeutics
  41. An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker.2023European journal of medical researchFree full text
  42. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.2023European journal of medical researchFree full text
  43. Comparative effectiveness of nipple-sparing mastectomy and breast-conserving surgery on long-term prognosis in breast cancer.2023Frontiers in endocrinologyFree full text
  44. Association between diabetes status and breast cancer in US adults: findings from the US National Health and Nutrition Examination Survey.2023Frontiers in endocrinologyFree full text
  45. Association between breast cancer and thyroid cancer risk: a two-sample Mendelian randomization study.2023Frontiers in endocrinologyFree full text
  46. Prognostic and immune implications of a novel 7-methylguanosine-related microRNA signature in breast invasive carcinoma: from exploration to validation.2023Journal of cancer research and clinical oncologyFree full text
  47. A novel RBBP8(p.E281*) germline mutation is a predisposing mutation in familial hereditary cancer syndrome.2023Journal of molecular medicine (Berlin, Germany)
  48. Pogostone attenuates osteolysis in breast cancer by inhibiting the NF-kB and JNK signaling pathways of osteoclast.2023Life sciences
  49. Identification of common genetic features and pathways involved in pulmonary lymphangioleiomyomatosis and ER-positive breast cancer.2023MedicineFree full text
  50. Identification of KCNK1 as a potential prognostic biomarker and therapeutic target of breast cancer.2023Pathology, research and practice
  51. A comprehensive analysis of the role of QPRT in breast cancer.2023Scientific reportsFree full text
  52. CD24-associated ceRNA network reveals prognostic biomarkers in breast carcinoma.2023Scientific reportsFree full text
  53. MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone-mediated autophagy.2023The FEBS journal
  54. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.2022Advances in therapy
  55. Prognosis Comparison Between Nipple-Sparing Mastectomy and Total Mastectomy in Breast Cancer: A Case-Control Study After Propensity Score Matching.2022Annals of surgical oncologyFree full text
  56. Aromatherapy Plus Music Therapy Improve Pain Intensity and Anxiety Scores in Patients With Breast Cancer During Perioperative Periods: A Randomized Controlled Trial.2022Clinical breast cancerRCT
  57. Al-MPS Obstructs EMT in Breast Cancer by Inhibiting Lipid Metabolism via miR-215-5p/SREBP1.2022Endocrinology
  58. Potentials of CCL21 and CBS as Therapeutic Approaches for Breast Cancer.2022European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes
  59. Autoantibodies as biomarkers for breast cancer diagnosis and prognosis.2022Frontiers in immunologyFree full text
  60. Co-expression of DDR2 and IFITM1 promotes breast cancer cell proliferation, migration and invasion and inhibits apoptosis.2022Journal of cancer research and clinical oncologyFree full text
  61. Downregulated Copper Homeostasis-Related Gene FOXO1 as a Novel Indicator for the Prognosis and Immune Response of Breast Cancer.2022Journal of immunology researchFree full text
  62. Orthotopic Versus Allotopic Implantation: Comparison of Radiological and Pathological Characteristics.2022Journal of magnetic resonance imaging : JMRIFree full text
  63. Psychometric properties of the Chinese version of the Courtauld Emotional Control Scale in women newly diagnosed with breast cancer.2022Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
  64. 3D reconstruction based novel methods are more effective than traditional clinical assessment in breast cancer axillary lymph node metastasis prediction.2022Scientific reportsFree full text
  65. Chemotherapy significantly improves long-term survival of small lesion node negative metaplastic breast carcinoma in T1c population rather than T1a and T1b.2022Scientific reportsFree full text
  66. Construction and validation of a risk prediction model for clinical axillary lymph node metastasis in T1-2 breast cancer.2022Scientific reportsFree full text
  67. PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer.2021BioMed research internationalFree full text
  68. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.2021Breast cancer research and treatment
  69. miR-937-5p targets SOX17 to modulate breast cancer cell cycle and cell proliferation through the Wnt signaling pathway.2021Cellular signalling
  70. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.2021Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  71. Coexpression of EphA10 and Gli3 promotes breast cancer cell proliferation, invasion and migration.2021Journal of investigative medicine : the official publication of the American Federation for Clinical ResearchFree full text
  72. N-Acetyl-L-cysteine Promotes Ex Vivo Growth and Expansion of Single Circulating Tumor Cells by Mitigating Cellular Stress Responses.2021Molecular cancer research : MCRFree full text
Chinese-language papers (not in the count)3
  1. Effects of ultrasonic rapid processing method on the protein, DNA, and RNA in paraffin-embedded tissues.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Research progress in decision-making aids for breast cancer patients.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status16
  1. Mechanistic Study of SPARC-Mediated Regulation of Neutrophil Extracellular Trap Formation in the Brain Metastatic Microenvironment of Breast CancerActive, not recruitingNCT07185646Lead sponsorStart 2023-01
  2. A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Study sitePhase 3Start 2025-09
  3. A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Study sitePhase 2/Phase 3Start 2025-06
  4. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationRecruitingNCT05696626Study sitePhase 3Start 2023-10
  5. Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression PatternsRecruitingNCT06551220Study siteStart 2022-10
  6. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Study sitePhase 4Start 2021-06
  7. FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerStatus unknownNCT05755048Study sitePhase 3Start 2023-03
  8. To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Study sitePhase 3Start 2022-07
  9. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Study sitePhase 3Start 2022-04
  10. Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382299Study sitePhase 3Start 2022-07
  11. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Study sitePhase 3Start 2022-03
  12. Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsStatus unknownNCT05145907Study sitePhase 2Start 2021-12
  13. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  14. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Study sitePhase 3Start 2016-11
  15. Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast CancerSuspendedNCT02897050Study sitePhase 2Start 2016-09
  16. A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]CompletedNCT02297438Study sitePhase 3Start 2015-03

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 20 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.3%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 6620232024: 4420242025: 222025

4 hospitals in Changsha for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led20
  1. GDNF-AS1 mediated LHX2/METTL3/NCOA4 axis inhibits glioma progression via induction of ferroptosis.2026Neurochemistry international
  2. Engineered nanovesicles targeting SERPINE1 overcome temozolomide resistance in glioblastoma.2025Cellular signalling
  3. Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis.2025Journal of nanobiotechnologyFree full text
  4. Comprehensive pancancer analysis reveals that LPCAT1 is a novel predictive biomarker for prognosis and immunotherapy response.2024Apoptosis : an international journal on programmed cell death
  5. A Histopathologic Correlation Study Evaluating Glymphatic Function in Brain Tumors by Multiparametric MRI.2024Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  6. Magnetic resonance imaging (MRI)-based intratumoral and peritumoral radiomics for prognosis prediction in glioma patients.2024Clinical radiology
  7. Integrative analysis of the cuproptosis-related gene ATP7B in the prognosis and immune infiltration of IDH1 wild-type glioma.2024Gene
  8. Temozolomide protects against the progression of glioblastoma via SOX4 downregulation by inhibiting the LINC00470-mediated transcription factor EGR2.2023CNS neuroscience & therapeuticsFree full text
  9. Superenhancers as master gene regulators and novel therapeutic targets in brain tumors.2023Experimental & molecular medicineFree full text
  10. Multi-omics analysis reveals the involvement of origin recognition complex subunit 6 in tumor immune regulation and malignant progression.2023Frontiers in immunologyFree full text
  11. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.2023Frontiers in immunologyFree full text
  12. A novel prognostic related lncRNA signature associated with amino acid metabolism in glioma.2023Frontiers in immunologyFree full text
  13. Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes.2023Journal of cancer research and clinical oncologyFree full text
  14. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models.2022Journal of magnetic resonance imaging : JMRIFree full text
  15. Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.2022Neuro-oncologyFree full text
  16. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion.2021Cell death & diseaseFree full text
  17. MicroRNA-361-5p slows down gliomas development through regulating UBR5 to elevate ATMIN protein expression.2021Cell death & diseaseFree full text
  18. Wash-free 3D imaging and detection of glioma with a novel neuropotential targeted AIE probe.2021Chemical communications (Cambridge, England)
  19. Exosomes and biomimetic nanovesicles-mediated anti-glioblastoma therapy: A head-to-head comparison.2021Journal of controlled release : official journal of the Controlled Release Society
  20. Multifunctional exosome-mimetics for targeted anti-glioblastoma therapy by manipulating protein corona.2021Journal of nanobiotechnologyFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Changsha for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led1
  1. Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells.2022Cell death & diseaseFree full text
Earlier papers (2016–2020)2
  1. Case Report: Adult Retinoblastoma Progression in 19 Months.2020Optometry and vision science : official publication of the American Academy of Optometry
  2. MALAT1 modulates the autophagy of retinoblastoma cell through miR-124-mediated stx17 regulation.2018Journal of cellular biochemistry
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownNCT04990271Study sitePhase 2Start 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 2 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Changsha for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Letter: Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery.2022Neurosurgery
  2. Letter to the editor of radiotherapy and oncology regarding the article "Carbon ion radiotherapy for sacral chordoma: A retrospective nationwide multicentre study in Japan" by Demizu et al.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Earlier papers (2016–2020)19
  1. The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma.2019Neurosurgery
  2. Clinicopathological and Prognostic Characteristics in Extra-Axial Chordomas: An Integrative Analysis of 86 Cases and Comparison With Axial Chordomas.2019Neurosurgery
  3. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.2019Neurosurgery
  4. Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients.2018Cancer immunology, immunotherapy : CII
  5. Letter to the Editor. Brachyury as prognostic biomarker in chordoma.2018Journal of neurosurgery
  6. CDK4 expression in chordoma: A potential therapeutic target.2018Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  7. Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER Registry from 1973 to 2014.2018Journal of orthopaedic surgery and research
  8. Letter: Cranial Chordoma: A New Preoperative Grading System.2018Neurosurgery
  9. Prognostic Factors in Clival Chordomas: An Integrated Analysis of 347 Patients.2018World neurosurgery
  10. Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.2018World neurosurgery
  11. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.2017Biochemical and biophysical research communications
  12. Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  13. Letter to the Editor: Influence of age on survival outcomes in patients with spinal chordoma.2017Journal of neurosurgery. Spine
  14. Prognostic factors in spinal chordoma: An update of current systematic review and meta-analysis.2017Journal of surgical oncology
  15. Letter: Factors Predicting Recurrence after Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities.2017Neurosurgery
  16. Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients.2017Neurosurgery
  17. Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature.2017World neurosurgery
  18. Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis.2017World neurosurgery
  19. Prognostic Biomarkers in Spinal Chordoma: A Systematic Review.2016Journal of neuropathology and experimental neurology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 43 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
43
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 8820212022: 131320222023: 2220232024: 111120242025: 882025

10 hospitals in Changsha for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgeryPathology / laboratory medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led43
  1. Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization.2026Advanced materials (Deerfield Beach, Fla.)
  2. Targeting Mitochondrial Oxidative Stress by Calcium/Copper/Elesclomol Tri-Overloaded Nanocages for Osteosarcoma Immunotherapy via Immunogenic Cell Death.2025ACS nano
  3. Assembly of a biomimetic copper-based nanocomplex for alleviating hypoxia to enhance cuproptosis against osteosarcoma and lung metastasis.2025Acta biomaterialia
  4. A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. Heterogeneity in Osteosarcoma Revealed by scRNA Sequencing: CLU+ Endothelial Cells as Key Players in Tumor Progression.2025Cancer scienceFree full text
  7. Ubiquitin-conjugating enzyme E2S (UBE2S) as a prognostic biomarker and regulator of tumorigenesis in osteosarcoma.2025International immunopharmacology
  8. Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma.2025Oncogene
  9. PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma.2025Signal transduction and targeted therapyFree full text
  10. Endoprosthetic replacement with preservation of the epiphysis for proximal tibial reconstruction after osteosarcoma resection in children: a case report.2024BMC musculoskeletal disordersFree full text
  11. PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT.2024Cancer researchFree full text
  12. RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis.2024Environmental toxicology
  13. SPP1 could be an immunological and prognostic biomarker: From pan-cancer comprehensive analysis to osteosarcoma validation.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  14. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis.2024Frontiers in immunologyFree full text
  15. The role of disulfidptosis-associated LncRNA-LINC01137 in Osteosarcoma Biology and its regulatory effects on macrophage polarization.2024Functional & integrative genomics
  16. RREB1 could act as an immunological and prognostic biomarker: From comprehensive analysis to osteosarcoma validation.2024International immunopharmacology
  17. Bibliometric analysis and visualisation of research hotspots and frontiers on omics in osteosarcoma.2024Journal of cancer research and clinical oncologyFree full text
  18. Identification and Validation of a Novel PANoptosis-related Gene Signatured for Osteosarcoma as Prognostic Model.2024Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  19. Radiomics analysis in differentiating osteosarcoma and chondrosarcoma based on T2-weighted imaging and contrast-enhanced T1-weighted imaging.2024Scientific reportsFree full text
  20. Machine learning survival prediction using tumor lipid metabolism genes for osteosarcoma.2024Scientific reportsFree full text
  21. The Eph/Ephrin system in primary bone tumor and bone cancer pain.2023AgingFree full text
  22. The BRD4-SRPK2-SRSF2 signal modulates the splicing efficiency of ACSL3 pre-mRNA and influences erastin-induced ferroptosis in osteosarcoma cells.2023Cell death & diseaseFree full text
  23. Circ_0003732 promotes osteosarcoma progression through regulating miR-377-3p/CPEB1 axis and Wnt/β-catenin signaling pathway.2022Anti-cancer drugs
  24. Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.2022Cell cycle (Georgetown, Tex.)Free full text
  25. Intelligent Segmentation Medical Assistance System for MRI Images of Osteosarcoma in Developing Countries.2022Computational and mathematical methods in medicineFree full text
  26. A Residual Fusion Network for Osteosarcoma MRI Image Segmentation in Developing Countries.2022Computational intelligence and neuroscienceFree full text
  27. Extraosseous Ewing Sarcoma of the Cervical Esophagus: Case Report and Literature Review.2022Ear, nose, & throat journal
  28. Knowledge atlas and emerging trends on ncRNAs of osteosarcoma: A bibliometric analysis.2022Frontiers in endocrinologyFree full text
  29. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.2022Frontiers in endocrinologyFree full text
  30. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.2022Frontiers in immunologyFree full text
  31. Effects of butein on human osteosarcoma cell proliferation, apoptosis, and autophagy through oxidative stress.2022Human & experimental toxicology
  32. Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma.2022International journal of nanomedicineFree full text
  33. Analysis of the subcellular location of FAM230B and its interaction with premature miR-302b in osteosarcoma.2022Journal of bone and mineral metabolism
  34. The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy.2022Journal of hematology & oncologyFree full text
  35. MicroRNA-143 expression inhibits the growth and the invasion of osteosarcoma.2022Journal of orthopaedic surgery and researchFree full text
  36. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma.2021BMC cancerFree full text
  37. The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.2021BMC cancerFree full text
  38. The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.2021BMC cancerFree full text
  39. Identification of potential micro-messenger RNAs (miRNA-mRNA) interaction network of osteosarcoma.2021BioengineeredFree full text
  40. Noncoding RNAs in osteosarcoma: Implications for drug resistance.2021Cancer letters
  41. TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation.2021Cell death & diseaseFree full text
  42. Diagnostic and Prognostic Significance of Dysregulated Expression of Circular RNAs in Osteosarcoma.2021Expert review of molecular diagnostics
  43. Long Noncoding RNA HCG9 Promotes Osteosarcoma Progression through RAD51 by Acting as a ceRNA of miR-34b-3p.2021Mediators of inflammationFree full text
Chinese-language papers (not in the count)4
  1. Application and mechanisms of targeting BRD4 in osteosarcoma.2025Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Downregulation of B4GALNT1 inhibits proliferation and metastasis of osteosarcoma cells.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Curcumin inhibits the proliferation and migration of osteosarcoma by regulating the expression of super-enhancer-associated genes.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  4. [Bioinformatics Analysis on Key Genes and Immune Infiltration of Osteosarcoma].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
Earlier papers (2016–2020)43
  1. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.2020Aging
  2. The regulatory effect of has-circ-0001146/miR-26a-5p/MNAT1 network on the proliferation and invasion of osteosarcoma.2020Bioscience reports
  3. The prognostic role of CD133 expression in patients with osteosarcoma.2020Clinical and experimental medicine
  4. Role of exosomal miR‑21 in the tumor microenvironment and osteosarcoma tumorigenesis and progression (Review).2020International journal of oncology
  5. Emerging landscape of circular RNAs as biomarkers and pivotal regulators in osteosarcoma.2020Journal of cellular physiology
  6. The Role of Chemotherapy in Extraskeletal Osteosarcoma: A Propensity Score Analysis of the Surveillance Epidemiology and End Results (SEER) Database.2020Medical science monitor : international medical journal of experimental and clinical research
  7. Predictors and Survival of Patients with Osteosarcoma After Limb Salvage versus Amputation: A Population-Based Analysis with Propensity Score Matching.2020World journal of surgery
  8. Mechanism of the Notch signaling pathway in enhancing the efficacy of chemotherapy drugs in osteosarcoma.2020Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  9. Association between PTEN and clinical-pathological features of osteosarcoma.2019Bioscience reports
  10. The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis.2019Cancer biology & therapy
  11. Characteristics and Prognostic Factors of Patients With Osteosarcoma Older Than 60 Years From the SEER Database.2019Cancer control : journal of the Moffitt Cancer Center
  12. miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b.2019Cell cycle (Georgetown, Tex.)
  13. Long non-coding RNA ZFAS1 regulates NOB1 expression through interacting with miR-646 and promotes tumorigenesis in osteosarcoma.2019European review for medical and pharmacological sciences
  14. MicroRNA-29a suppresses the invasion and migration of osteosarcoma cells by regulating the SOCS1/NF-κB signalling pathway through negatively targeting DNMT3B.2019International journal of molecular medicine
  15. MAT1 facilitates the lung metastasis of osteosarcoma through upregulation of AKT1 expression.2019Life sciences
  16. A case report of primary osteosarcoma originating from kidney.2019Medicine
  17. Evaluation of the Efficacy of Pasteurized Autograft and Intramedullary Vascularized Fibular Transfer for Osteosarcoma of the Femoral Diaphysis.2019Orthopaedic surgery
  18. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.2019World neurosurgery
  19. [Suppression of miR-30a/HMGA2-mediated autophagy in osteosarcoma cells impacts chemotherapeutics-induced apoptosis].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  20. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.2018Biochemical and biophysical research communications
  21. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  22. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  23. Identification of potential crucial genes and construction of microRNA-mRNA negative regulatory networks in osteosarcoma.2018Hereditas
  24. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition.2018Journal of experimental & clinical cancer research : CR
  25. The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma.2018Molecular medicine reports
  26. The potential combinational effect of miR-34a with celecoxib in osteosarcoma.2017Anti-cancer drugs
  27. MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p.2017Cell cycle (Georgetown, Tex.)
  28. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  29. Actin-like protein 6A is a novel prognostic indicator promoting invasion and metastasis in osteosarcoma.2017Oncology reports
  30. Pasteurized autograft reconstruction after resection of periacetabular malignant bone tumours.2017World journal of surgical oncology
  31. Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells.2016Cancer science
  32. SerpinE2 promotes multiple cell proliferation and drug resistance in osteosarcoma.2016Molecular medicine reports
  33. Protein inhibitor of activated STAT xα depresses cyclin D and cyclin D kinase, and contributes to the inhibition of osteosarcoma cell progression.2016Molecular medicine reports
  34. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.2016Oncotarget
  35. Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.2016Oncotarget
  36. mTOR: An attractive therapeutic target for osteosarcoma?2016Oncotarget
  37. Hypoxia-inducible factor-1 expression predicts osteosarcoma patients' survival: a meta-analysis.2016The International journal of biological markers
  38. miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  39. Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  40. Total femoral reconstruction with custom prosthesis for osteosarcoma.2016World journal of surgical oncology
  41. Image and pathological features of Ewing's sarcoma in the oral and maxillofacial region.2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  42. [Efficacy of reconstruction with modular endoprosthesis after resection of periacetabular malignant tumors].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  43. [miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 112025

3 hospitals in Changsha for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 5 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 0020242025: 002025

7 hospitals in Changsha for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyNeurosurgery

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Changsha for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Papers it led1
  1. Extraosseous Ewing Sarcoma of the Cervical Esophagus: Case Report and Literature Review.2022Ear, nose, & throat journal
Earlier papers (2016–2020)3
  1. Pasteurized autograft reconstruction after resection of periacetabular malignant bone tumours.2017World journal of surgical oncology
  2. Image and pathological features of Ewing's sarcoma in the oral and maxillofacial region.2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  3. [Efficacy of reconstruction with modular endoprosthesis after resection of periacetabular malignant tumors].2016Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 14 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.8%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 3320232024: 3320242025: 222025

4 hospitals in Changsha for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Posted
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinationsDiagnosis, MRD & riskStem cell transplant
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Papers it led14
  1. IRF4 (MUM1) in B-cell malignancies: molecular mechanisms, biological functions, and clinical implications.2026Pathology
  2. The function and mechanism of clinical trial agent CPI-613 in multiple myeloma.2025Biochemical pharmacology
  3. Enhancing staging in multiple myeloma using an m6A regulatory gene-pairing model.2025Clinical and experimental medicineFree full text
  4. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.2024Blood cancer journalFree full text
  5. Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets.2024Cell death & diseaseFree full text
  6. Enhancing multiple myeloma staging: a novel cell death risk model approach.2024Clinical and experimental medicineFree full text
  7. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.2023Blood advancesFree full text
  8. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database.2023Clinical pharmacology and therapeutics
  9. LINC00461 Knockdown Enhances the Effect of Ixazomib in Multiple Myeloma Cells.2023Current cancer drug targets
  10. CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77.2022Bioorganic chemistry
  11. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.2022Cancer letters
  12. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.2021Advances in therapy
  13. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.2021Cancer letters
  14. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis.2021Clinical therapeutics
Chinese-language papers (not in the count)1
  1. Diagnosis and treatment of multiple myeloma in Hunan Province.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  2. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  3. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  4. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 3 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

4 hospitals in Changsha for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Posted
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsCAR-T & cell therapy

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 6 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 2220232024: 1120242025: 002025

2 hospitals in Changsha for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunosuppressive treatmentThrombopoietin drugsChildren
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

4 hospitals in Changsha for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantEBV & infection triggersChildren
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 13 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
10
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 6620232024: 4420242025: 112025

5 hospitals in Changsha for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07441993

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou

  3. Recruiting
    Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06854445

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  4. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  5. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  6. Recruiting
    A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06136559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou

  7. Recruiting
    A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Phase
    Phase 3
    Started
    2022-07
    Posted
    Registry
    NCT05254743

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan

  8. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  9. Recruiting
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
    Phase
    Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04728893

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  10. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineGastroenterology / hepatologyMedical oncologyRheumatology & immunology
Papers it led13
  1. IRF4 (MUM1) in B-cell malignancies: molecular mechanisms, biological functions, and clinical implications.2026Pathology
  2. Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.2025Current treatment options in oncology
  3. Primary rectal Hodgkin lymphoma mimicking neuroendocrine tumor successfully removed by endoscopic submucosal dissection.2024Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  4. Plasmablastic lymphoma: current knowledge and future directions.2024Frontiers in immunologyFree full text
  5. Plasma metabolites in childhood Burkitt lymphoma cases and cancer-free controls in Uganda.2024Metabolomics : Official journal of the Metabolomic SocietyFree full text
  6. Pulmonary mucosa-associated lymphoid tissue lymphoma: insights from a 15-year study at a single institution involving 14 clinical cases.2024World journal of surgical oncologyFree full text
  7. Clonal architecture and single-cell transcriptome landscape in Richter's syndrome.2023British journal of haematology
  8. Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma.2023Clinical and experimental medicine
  9. NK/T-cell lymphoma with rash and peripheral neuropathy as the first manifestation: a case report and literature review.2023Diagnostic pathologyFree full text
  10. Identification of a novel model based on ferroptosis-related genes for predicting the prognosis of diffuse large B-cell lymphomas.2023Hematology (Amsterdam, Netherlands)
  11. Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL.2023Leukemia research
  12. The Aurora kinase inhibitor AT9283 inhibits Burkitt lymphoma growth by regulating Warburg effect.2023PeerJFree full text
  13. Research progress on epigenetics of small B-cell lymphoma.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Chinese-language papers (not in the count)2
  1. [Transformation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia into diffuse large B-cell lymphoma: five cases report and literature review].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Analysis and reflections on the current status of diagnosis and treatment of marginal zone lymphoma].2024Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status18
  1. Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingNCT07441993Study sitePhase 2Start 2026-01
  2. A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Study sitePhase 3Start 2026-03
  3. Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaNot yet recruitingNCT07896590Study sitePhase 3Start 2026-10
  4. A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07189065Study sitePhase 2Start 2025-11
  5. Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaRecruitingNCT06854445Study sitePhase 2Start 2025-03
  6. ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Study sitePhase 2/Phase 3Start 2024-05
  7. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingNCT06136559Study sitePhase 3Start 2023-12
  8. A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Study sitePhase 3Start 2022-07
  9. Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Study sitePhase 1/Phase 2Start 2022-05
  10. Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Study sitePhase 2Start 2021-04
  11. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsActive, not recruitingNCT06970743Study sitePhase 3Start 2025-05
  12. A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaStatus unknownNCT05234684Study sitePhase 3Start 2022-11
  13. Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05479994Study sitePhase 2Start 2022-10
  14. A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Study sitePhase 3Start 2021-09
  15. ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLStatus unknownNCT04578613Study sitePhase 3Start 2021-01
  16. A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04808570Study sitePhase 1/Phase 2Start 2021-06
  17. Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Study sitePhase 2Start 2021-04
  18. Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibCompletedNCT05068440Study sitePhase 2Start 2021-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

5 hospitals in Changsha for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Changsha for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Changsha for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Changsha for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 5 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 7.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 2220232024: 0020242025: 002025

2 hospitals in Changsha for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 7 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.4%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 1120242025: 002025

2 hospitals in Changsha for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisImagingPregnancy, children, older adults
Departments in papersNeurologyRadiology / nuclear medicinePediatricsOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 1 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Changsha for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07222553

    Age 2 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changsha

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesHead, eye socket & salivary glandsKidney, retroperitoneum & vessels
Departments in papersOphthalmology / neuro-ophthalmologyPathology / laboratory medicine
Papers it led1
  1. IgG4-related ophthalmic disease masquerading as ciliary body tumors and scleritis in both eyes: a case report.2023BMC ophthalmologyFree full text
Chinese-language papers (not in the count)2
  1. Clinical characteristics of IgG4-related disease with lung involvement in 14 patients.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Lung adenocarcinoma misdiagnosed as IgG4-related lung disease: A case report and literature review.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDNot yet recruitingNCT07222553Study sitePhase 2Start 2026-10
More papers found outside PubMed (not counted)1
  1. A Rare Case of IgG4-related Disease Manifesting as an Ulcerated Gastric Cancer Complicated With Gastric Mucormycosis2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 6 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 2220242025: 112025

4 hospitals in Changsha for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThymus & thymectomyAntibodies & diagnosisStandard immunotherapy
Departments in papersNeurologyNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 7 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 3.5%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 1120242025: 222025

1 hospital in Changsha for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Diagnosis & copper testsChildren
Departments in papersOphthalmology / neuro-ophthalmologyGastroenterology / hepatologyNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 36 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.7%.

Papers led
36
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 9920212022: 5520222023: 3320232024: 111120242025: 772025

4 hospitals in Changsha for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07521007

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  2. Not yet recruiting
    Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG
    Phase
    N/A
    Started
    2026-12
    Posted
    Registry
    NCT07918781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Nanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrologyRadiology / nuclear medicine
Papers it led36
  1. The feasibility and accuracy of planning the length of grafts of coronary artery bypass grafting using syngo.via based on CCTA.2026International journal of surgery (London, England)
  2. Risk factors for and a preliminary prediction model of coronary artery calcification in patients beginning hemodialysis.2025European journal of medical researchFree full text
  3. The role of lactate and lactylation in ischemic cardiomyopathy: Mechanisms and gene expression.2025Experimental and molecular pathology
  4. Changes in Treg cells and cytokines in the peripheral blood of patients with coronary artery disease combined with type 2 diabetes mellitus.2025Heart & lung : the journal of critical care
  5. Analysis risk factors of long-term adverse outcomes and a prediction nomogram for coronary artery disease patients underwent fractional flow reserve.2025International journal of medical sciencesFree full text
  6. Aerobic exercise alleviates statin-induced PCSK9 upregulation by increasing epoxyeicosatrienoic acid levels through the FoxO3a-Sirt6 axis.2025Journal of sport and health scienceFree full text
  7. The impact of hyperglycemia on prognosis in chronic obstructive pulmonary disease patients with coronary heart disease: A five-year prospective study.2025PloS oneFree full text
  8. Mediating effect of dietary self-efficacy in the relationship between health literacy and nutrition label use among coronary heart disease patients.2025Scientific reportsFree full text
  9. Visceral and subcutaneous adiposity and cardiovascular disease: Unravelling associations and prognostic value.2024Diabetes, obesity & metabolism
  10. Expression patterns and clinical value of key m6A RNA modification regulators in smoking patients with coronary artery disease.2024EpigeneticsFree full text
  11. Metformin-Induced Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition Further Decreases Low-Density Lipoprotein Cholesterol Following Statin Treatment in Patients With Coronary Artery Disease and Without Diabetes.2024Journal of cardiovascular pharmacologyRCT
  12. Investigation of clinical significance of ST-segment depression during paroxysmal supraventricular tachycardia.2024Journal of electrocardiology
  13. Assessment of Myocardial Viability and Risk Stratification in Coronary Chronic Total Occlusion: A Qualitative and Quantitative Stress Cardiac MRI Study.2024Journal of magnetic resonance imaging : JMRI
  14. There Is No Direct Causal Relationship Between Coronary Artery Disease and Alzheimer Disease: A Bidirectional Mendelian Randomization Study.2024Journal of the American Heart AssociationFree full text
  15. Triglyceride to high-density lipoprotein cholesterol ratio associated with long-term adverse clinical outcomes in patients deferred revascularization following fractional flow reserve.2024Lipids in health and diseaseFree full text
  16. The serum soluble ASGR1 concentration is elevated in patients with coronary artery disease and is associated with inflammatory markers.2024Lipids in health and diseaseFree full text
  17. A high level of uric acid is associated with long-term adverse cardiovascular outcomes in patients who received fractional flow reserve with coronary intermediate stenosis.2024Nutrition, metabolism, and cardiovascular diseases : NMCD
  18. Effects of childhood obesity on heart failure and its associated risk factors in the European population: A Mendelian randomization study.2024Nutrition, metabolism, and cardiovascular diseases : NMCD
  19. Cheese consumption on atherosclerosis, atherosclerotic cardiovascular diseases and its complications: A two-sample Mendelian randomization study.2024Nutrition, metabolism, and cardiovascular diseases : NMCD
  20. Serum soluble TREM2 is an independent biomarker associated with coronary heart disease.2023Clinica chimica acta; international journal of clinical chemistry
  21. Intensive Lipid-Lowering Therapy as per the Latest Dyslipidemia Management Guideline in Predicting Favorable Long-Term Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Grafting: A Retrospective Cohort Study.2023Journal of the American Heart AssociationFree full text
  22. The clinical effect of Xuezhikang combined with ezetimibe in the treatment of coronary heart disease in lipid-lowering treatment and its influence on blood lipid level.2023Panminerva medica
  23. The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease.2022Cardiovascular drugs and therapyRCT
  24. Effectiveness of micro-lecture based cardiac rehabilitation education on health status in individuals with coronary artery disease: A randomized clinical trial.2022Clinical rehabilitationRCT
  25. Genetic analysis of potential biomarkers and therapeutic targets in ferroptosis from coronary artery disease.2022Journal of cellular and molecular medicineFree full text
  26. Clinical and economic burden of comorbid coronary artery disease in patients with acute exacerbation of chronic obstructive pulmonary disease: sex differences in a nationwide cohort study.2022Respiratory researchFree full text
  27. Non-fasting changes of Hs-CRP level in Chinese patients with coronary heart disease after a daily meal.2022Scientific reportsFree full text
  28. Coronary artery fistula and bronchiectasis: case report and literature review.2021Annals of palliative medicine
  29. Roles of MicroRNAs in Peripheral Artery In-Stent Restenosis after Endovascular Treatment.2021BioMed research internationalFree full text
  30. Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the "Prime Time" of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?2021Cardiovascular drugs and therapy
  31. The association of interferon-alpha with development of collateral circulation after artery occlusion.2021Clinical cardiologyFree full text
  32. Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis.2021Drugs
  33. Short-term and long-term outcomes of revascularization interventions for patients with severely reduced left ventricular ejection fraction: a meta-analysis.2021ESC heart failureFree full text
  34. The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease.2021Frontiers in endocrinologyFree full text
  35. Systematic Review and Meta-analysis: The Effects of Prophylactic Proton Pump Inhibitor Treatment in Patients With Coronary Heart Disease Receiving Dual Antiplatelet Therapy.2021Journal of cardiovascular pharmacology
  36. Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials.2021Journal of cardiovascular pharmacology
Chinese-language papers (not in the count)2
  1. Chest pain caused by left coronary artery spasm in a patient with anomalous origin of right coronary artery.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. 1H-NMR-based metabolomics study on coronary heart disease with blood-stasis syndrome and phlegm syndrome.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABGNot yet recruitingNCT07918781Study siteN/AStart 2026-12
  2. A Phase 2b Clinical Trial of YN001 in Adults With Coronary AtherosclerosisRecruitingNCT07521007Study sitePhase 2Start 2026-07
  3. Phitys I™ Percutaneous Left Ventricular Assist System StudyStatus unknownNCT06357026Study siteN/AStart 2024-04
  4. Phimume® Percutaneous Left Ventricular Assist System StudyStatus unknownNCT06639321Study siteN/AStart 2024-10
  5. Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery DiseaseActive, not recruitingNCT03977129Study siteN/AStart 2019-08
  6. The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for VicagrelCompletedNCT03599284Study sitePhase 2Start 2018-08
  7. Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)Status unknownNCT02448524Study sitePhase 3Start 2015-07
  8. A Trial to Evaluate Efficacy of Heart-protecting Musk PillStatus unknownNCT01897805Study sitePhase 4Start 2011-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 40 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 1.5%.

Papers led
40
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 111120212022: 6620222023: 7720232024: 8820242025: 882025

6 hospitals in Changsha for congenital heart disease207 hospitals in China for congenital heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07363538

    Age Not stated to 7 days (registered criteria)

    Led by Central China Fuwai Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Qingdao, Shanghai, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePediatricsNephrology
Papers it led40
  1. Application of fibrobronchoscopy-guided aortic suspension in pediatric patients with bronchial compression resulting from repair of coarctation of the aorta: a case report.2025BMC pediatricsFree full text
  2. Vortex formation of cardiac bilateral ventricles in fetuses with tetralogy of fallot assessed by blood speckle-tracking echocardiography.2025BMC pregnancy and childbirthFree full text
  3. Transcatheter hybrid closure of a large muscular ventricular septal defect with severe pulmonary hypertension using a duct occluder.2025Clinical and experimental hypertension (New York, N.Y. : 1993)
  4. Long-term survival of shunt closure in atrial septal defects with pulmonary arterial hypertension.2025International journal of cardiology
  5. Trends and advances in cardiac rehabilitation for congenital heart disease: a bibliometric analysis.2025Journal of cardiothoracic surgeryFree full text
  6. The prevalence of laterality defects in patients with congenital heart disease.2025Journal of human genetics
  7. Impaired Pulmonary Arterial Elasticity and Ventricular Function in Fetuses With Tetralogy of Fallot.2025Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  8. Abnormal flow patterns in ascending aorta in fetuses with tetralogy of Fallot: evaluation by blood speckle-tracking echocardiography.2025Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  9. Intracardiac Echocardiography and Ablation of Atrial Fibrillation in Dextrocardia.2024Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, IncFree full text
  10. Comparison between conventional approach and three-dimensional mapping system in the catheter ablation of accessory pathway associated with coronary sinus diverticulum: A single-center experience.2024Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, IncFree full text
  11. A case of pioneering subcutaneous implantable cardioverter defibrillator intervention in Timothy syndrome.2024BMC pediatricsFree full text
  12. 20p chromosome inverted duplication syndrome with phenotypes of congenital heart disease, anorectal malformation and megacolon.2024BMJ case reports
  13. Identification of a novel MYO1D variant associated with laterality defects, congenital heart diseases, and sperm defects in humans.2024Frontiers of medicine
  14. The association between patent foramen ovale and unexplained syncope in pediatric patients.2024Italian journal of pediatricsFree full text
  15. Assessment of Pulmonary Arterial Vascular Impedance in Fetuses With Tetralogy of Fallot.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  16. Left Ventricular Vortex Characteristics in Fetuses With Coarctation of the Aorta by Blood Speckle-Tracking Echocardiography.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  17. Successful Eisenmenger syndrome-targeted drug therapy in pregnant women: a case series and literature review.2023BJOG : an international journal of obstetrics and gynaecology
  18. Prenatal diagnosis: Hypoplastic left heart syndrome in combination with ventriculo-coronary communication.2023Birth defects research
  19. Association of underweight and obesity with adverse postoperative renal outcomes in infants and young children undergoing congenital heart surgery.2023European journal of pediatrics
  20. Impaired Distensibility of the Proximal Aorta in Fetuses With Tetralogy of Fallot.2023Journal of the American Heart AssociationFree full text
  21. Impaired Elastic Properties of the Ascending Aorta in Fetuses With Coarctation of the Aorta.2023Journal of the American Heart AssociationFree full text
  22. Visualizable intracardiac flow pattern in fetuses with congenital heart defect: pilot study of blood speckle-tracking echocardiography.2023Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  23. Impaired ascending aortic elasticity in fetuses with tetralogy of Fallot.2023Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  24. Atrial septal defect with a rare occupying lesion in heart.2022BMC cardiovascular disordersFree full text
  25. Type II Left Pulmonary Artery Sling Associated with Double-Outlet Right Ventricle Diagnosed by Fetal Echocardiography and Postnatal Computer Tomography.2022Fetal diagnosis and therapy
  26. Successful biventricular repair in a 14-year-old patient of asplenia with congenital heart disease syndrome.2022Journal of cardiac surgery
  27. A novel nonsense PKD1L1 variant cause heterotaxy syndrome with congenital asplenia in a Han Chinese patient.2022Journal of human genetics
  28. Individualized right ventricular outflow tract reconstruction using autologous pulmonary tissue in situ for the treatment of pulmonary atresia with ventricular septum defect.2022Reviews in cardiovascular medicine
  29. Association between maternal oxygenation and brain growth in fetuses with left-sided cardiac obstructive lesions.2022Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  30. The M310T mutation in the GATA4 gene is a novel pathogenic target of the familial atrial septal defect.2021BMC cardiovascular disordersFree full text
  31. Effects of minimally invasive and traditional surgeries on the quality of life of children with congenital heart disease: a retrospective propensity score-matched study.2021BMC pediatricsFree full text
  32. Results of two different echocardiography-guided approaches to closure of perimembranous ventricular septal defects.2021European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  33. A young man with precordial continuous murmur.2021Heart (British Cardiac Society)
  34. Long-term outcomes of mitral valve replacement in patients weighing less than 10 kg.2021Journal of cardiothoracic surgeryFree full text
  35. Isolated ventricular apical hypoplasia: A report of four cases and literature review.2021Journal of clinical ultrasound : JCU
  36. Application of 3D printing technology combined with PBL teaching model in teaching clinical nursing in congenital heart surgery: A case-control study.2021MedicineFree full text
  37. Whole-exome sequencing identified a novel homozygous ASPH frameshift variant causing Traboulsi syndrome in a Chinese family.2021Molecular genetics & genomic medicineFree full text
  38. The Right Thoracic Incision: The Importance of Children's Thoracic Deformity and Thymus Dysplasia.2021The Annals of thoracic surgery
  39. A large congenital atrial septal defect in an adult with delayed therapy.2021The Journal of international medical researchFree full text
  40. Surgical Management of a Giant Left Sinus of Valsalva Aneurysm with Coronary Artery Abnormality.2021The heart surgery forum
Chinese-language papers (not in the count)9
  1. [Adult congenital heart disease misdiagnosed as Eisenmenger syndrome: a case report].2025Zhonghua xin xue guan bing za zhi
  2. Midterm follow-up results of implantation of a fully biodegradable ventricular septal defect occluder.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  3. Echocardiographic features and pathological ultrastructural characteristics of fetal interruption of aortic arch.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  4. Comparison between the modified Blalock-Taussig shunt and right ventricular outflow tract stent in the palliative treatment for tetralogy of Fallot.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  5. Clinical manifestations and computed tomography angiography features of anomalous left coronary artery from the pulmonary artery syndrome.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  6. [A case with tetralogy of Fallot and thymus hypoplasia found by ultrasound was eventually diagnosed as DiGeorge syndrome].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
  7. Clinical phenotypes of primary ciliary dyskinesia.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  8. Clinical factors affecting the early postoperative prognosis of infants suffering surgery for congenital heart diseases: A single-center experience of 511 patients.2022Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  9. Application value of echocardiography in transthoracic punctural closure of postoperative residual ventricular septal defect of congenital heart disease.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart DiseaseRecruitingNCT07363538Study siteN/AStart 2025-12
  2. A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) ClosureStatus unknownNCT03941691Study siteN/AStart 2019-04
  3. Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD PatientsCompletedNCT03601039Study siteN/AStart 2018-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led 5 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 222025

3 hospitals in Changsha for scoliosis107 hospitals in China for scoliosis

No open trial on scoliosis lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 3 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

3 hospitals in Changsha for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurologyNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 5 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 2.7%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 0020242025: 002025

3 hospitals in Changsha for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 18 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.8%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 7720232024: 5520242025: 222025

6 hospitals in Changsha for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led18
  1. The impact of psoriasis on idiopathic pulmonary fibrosis: a two-sample Mendelian randomization study.2025International journal of dermatology
  2. RTN3 regulates collagen biosynthesis and profibrotic macrophage differentiation to promote pulmonary fibrosis via interacting with CRTH2.2025Molecular medicine (Cambridge, Mass.)Free full text
  3. Molecular characterization of PANoptosis-related genes associated with immune infiltration and prognosis in idiopathic pulmonary fibrosis.2024International immunopharmacology
  4. ZCCHC8 p.P410A disrupts nucleocytoplasmic localization, promoting idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.2024Molecular medicine (Cambridge, Mass.)Free full text
  5. The prognostic role of high-density lipoprotein cholesterol/C-reactive protein ratio in idiopathic pulmonary fibrosis.2024QJM : monthly journal of the Association of PhysiciansFree full text
  6. A nonsense mutation (c.382C>T) of PARN in a patient with idiopathic pulmonary fibrosis.2024QJM : monthly journal of the Association of Physicians
  7. Prevalence and prognostic value of malnutrition in patients with IPF using three scoring systems.2024Respiratory medicine
  8. A novel mutation (p.Y24N) in NHP2 leads to idiopathic pulmonary fibrosis and lung carcinoma chronic obstructive lung disease by disrupting the expression and nucleocytoplasmic localization of NHP2.2023Biochimica et biophysica acta. Molecular basis of disease
  9. CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential.2023BiomoleculesFree full text
  10. Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway.2023Experimental gerontology
  11. Analysis of necroptosis-related prognostic genes and immune infiltration in idiopathic pulmonary fibrosis.2023Frontiers in immunologyFree full text
  12. Mitochondrial fission and bioenergetics mediate human lung fibroblast durotaxis.2023JCI insightFree full text
  13. Eupatilin inhibits pulmonary fibrosis by activating Sestrin2/PI3K/Akt/mTOR dependent autophagy pathway.2023Life sciences
  14. Integrative analysis reveals the recurrent genetic etiologies in idiopathic pulmonary fibrosis.2023QJM : monthly journal of the Association of Physicians
  15. DNA methylation in pulmonary fibrosis and lung cancer.2022Expert review of respiratory medicineFree full text
  16. Cofilin-1 promotes fibrocyte differentiation and contributes to pulmonary fibrosis.2021Biochemical and biophysical research communications
  17. Construction and validation of a bronchoalveolar lavage cell-associated gene signature for prognosis prediction in idiopathic pulmonary fibrosis.2021International immunopharmacology
  18. Associations Between Diabetes and Idiopathic Pulmonary Fibrosis: a Study-level Pooled Analysis of 26 Million People.2021The Journal of clinical endocrinology and metabolism
Chinese-language papers (not in the count)1
  1. Clinical evaluation on idiopathic pulmonary fibrosis.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
Earlier papers (2016–2020)4
  1. MeCP2 epigenetically regulates alpha-smooth muscle actin in human lung fibroblasts.2020Journal of cellular biochemistry
  2. Glutaminolysis Epigenetically Regulates Antiapoptotic Gene Expression in Idiopathic Pulmonary Fibrosis Fibroblasts.2019American journal of respiratory cell and molecular biology
  3. Cigarette Smoke Extract Promotes Human Lung Myofibroblast Differentiation by the Induction of Endoplasmic Reticulum Stress.2019Respiration; international review of thoracic diseases
  4. Idiopathic Pulmonary Fibrosis: A Systemic Disease?2017Chinese medical journal
All its trials on ClinicalTrials.gov, any status11
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  5. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  6. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  7. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  8. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  9. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  10. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08
  11. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 3 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 6.7%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

1 hospital in Changsha for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Changsha for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Changsha for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Fbxl3 deletion mitigates myopathy in mdx mice through upregulation of myogenin.2025Biochemical and biophysical research communications

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Changsha for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 14 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
14
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 5520232024: 1120242025: 222025

7 hospitals in Changsha for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led14
  1. Single-Cell RNA-Sequencing Analysis Provides Insights into IgA Nephropathy.2025BiomoleculesFree full text
  2. The predictive value of suPAR for glomerular segmental sclerosis lesions in renal pathology.2025Renal failureFree full text
  3. Mechanistic study of celastrol-mediated inhibition of proinflammatory activation of macrophages in IgA nephropathy via down-regulating ECM1.2024International journal of biological sciencesFree full text
  4. Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis.2023BMC medical genomicsFree full text
  5. EIF2α/ATF4 pathway enhances proliferation of mesangial cell via cyclin D1 during endoplasmic reticulum stress in IgA nephropathy.2023Clinical immunology (Orlando, Fla.)
  6. Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy.2023Drug design, development and therapyFree full text
  7. Clinical and pathological features of omicron variant of SARS-CoV-2-associated kidney injury.2023Journal of medical virology
  8. Changes in spectrum of biopsy-proven kidney diseases within decade: an analysis based on 10 199 cases from South China.2023Postgraduate medical journal
  9. Triptolide promotes autophagy to inhibit mesangial cell proliferation in IgA nephropathy via the CARD9/p38 MAPK pathway.2022Cell proliferationFree full text
  10. The influences of α-hemolytic Streptococcus on class switching and complement activation of human tonsillar cells in IgA nephropathy.2022Immunologic research
  11. Efficacy and indications of tonsillectomy in patients with IgA nephropathy: a retrospective study.2022PeerJFree full text
  12. Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study.2021BMC nephrologyFree full text
  13. Clinical implication of the circumferential crescents lesions in immunoglobulin A nephropathy: a single-center study of Han Chinese population.2021Human pathology
  14. Downregulation of miR‑214-3p attenuates mesangial hypercellularity by targeting PTEN‑mediated JNK/c-Jun signaling in IgA nephropathy.2021International journal of biological sciencesFree full text
Chinese-language papers (not in the count)2
  1. Regulatory role of the mTOR signaling pathway in autophagy and mesangial proliferation in IgA nephropathy.2024Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. Clinical outcomes for kidney transplantation in 81 adults with IgA nephropathy.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
Earlier papers (2016–2020)20
  1. Coagulation parameters are associated with the prognosis of immunoglobulin a nephropathy: a retrospective study.2020BMC nephrology
  2. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.2020Clinical immunology (Orlando, Fla.)
  3. microRNA-630 Regulates Underglycosylated IgA1 Production in the Tonsils by Targeting TLR4 in IgA Nephropathy.2020Frontiers in immunology
  4. Association analysis of DNA methyltransferases in IgA nephropathy.2020International immunopharmacology
  5. Dihydroartemisinin inhibits the proliferation of IgAN mesangial cells through the mTOR signaling pathway.2020International immunopharmacology
  6. The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis.2020International urology and nephrology
  7. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.2020Medical science monitor : international medical journal of experimental and clinical research
  8. Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy.2019American journal of nephrology
  9. Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy.2019International immunopharmacology
  10. [Clinicopathological analysis for IgA nephropathy with isolated hematuria and/or mild proteinuria].2019Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  11. Impact of GADD34 on Apoptosis of Tonsillar Mononuclear Cells from IgA Nephropathy Patients by Regulating Eif2α Phosphorylation.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  12. Prediction of ESRD in IgA Nephropathy Patients from an Asian Cohort: A Random Forest Model.2018Kidney & blood pressure research
  13. Rapamycin Enhances Repressed Autophagy and Attenuates Aggressive Progression in a Rat Model of IgA Nephropathy.2017American journal of nephrology
  14. Serum D-dimer is a potential predictor for thromboembolism complications in patients with renal biopsy.2017Scientific reports
  15. Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy.2017Scientific reports
  16. p53 induces miR199a-3p to suppress SOCS7 for STAT3 activation and renal fibrosis in UUO.2017Scientific reports
  17. Regulation of IgA Class Switch Recombination in Immunoglobulin A Nephropathy: Retinoic Acid Signaling and BATF.2016American journal of nephrology
  18. Potential diagnostic biomarkers for IgA nephropathy: a comparative study pre- and post-tonsillectomy.2016International urology and nephrology
  19. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial.2016Renal failureRCT
  20. Efficacy of triptolide on the apoptosis of tonsillar mononuclear cells from patients with IgA nephropathy.2016Renal failure
All its trials on ClinicalTrials.gov, any status3
  1. Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.Status unknownNCT02187900Lead sponsorPhase 3Start 2014-06
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Changsha for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07557446

    Age 12 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)RecruitingNCT07557446Study sitePhase 2Start 2026-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changsha for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. [Meta Analysis of Risks of Cardiocerebral Vascular Events in Patients with Primary Biliary Cholangitis].2019Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  2. Histone Posttranslational Modifications of CD4⁺ T Cell in Autoimmune Diseases.2016International journal of molecular sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Changsha for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中南大学湘雅二医院

Second Xiangya Hospital

长沙

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Xiangya Hospital of Central South University; Second Xiangya Hospital of Central South Unive; second Xiangya Hospital; Guilin Hospital of the Second Xiangya Hospital; Second Xiangya Hospital of Central-South University

Suggest a correctionDownload the data